1
|
García-Esteban JA, Curto B, Moreno V, Hernández F, Alonso P, Serrano FJ, Blanco FJ. Real needle for minimal invasive procedures training using motion sensors and optical flow. Comput Biol Med 2024; 170:107935. [PMID: 38215620 DOI: 10.1016/j.compbiomed.2024.107935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 11/24/2023] [Accepted: 01/01/2024] [Indexed: 01/14/2024]
Abstract
Minimally invasive percutaneous insertion procedures are widely used techniques in medicine. Their success is highly dependent on the skills of the practitioner. This paper presents a haptic simulator for training in these procedures, whose key component is a real percutaneous insertion needle with a sensory system incorporated to track its 3D location at every instant. By means of the proposed embedded vision system, the attitude (spatial orientation) and depth of insertion of a real needle are estimated. The proposal is founded on a novel depth estimation procedure based on optical flow techniques, complemented by sensory fusion techniques with the attitude calculated with data from an Inertial Measurement Unit (IMU) sensor. This procedure allows estimating the needle attitude with an accuracy of tenths of a degree and the displacement with an accuracy of millimeters. The computational algorithm runs on an embedded computer with real-time constraints for tracking the movement of a real needle. This haptic needle location data is used to reproduce the movement of a virtual needle within a simulation app. As a fundamental result, an ergonomic and realistic training simulator has been successfully constructed for healthcare professionals to acquire the mental model and motor skills necessary to practice percutaneous procedures successfully.
Collapse
Affiliation(s)
- J A García-Esteban
- Dpt. Computers and Automation, University of Salamanca, Plaza de los Caídos S/N, Salamanca, 37008, Spain.
| | - B Curto
- Dpt. Computers and Automation, University of Salamanca, Plaza de los Caídos S/N, Salamanca, 37008, Spain.
| | - V Moreno
- Dpt. Computers and Automation, University of Salamanca, Plaza de los Caídos S/N, Salamanca, 37008, Spain.
| | - F Hernández
- University Clinical Hospital of Salamanca, Paseo San Vicente 182, Salamanca, 37007, Spain.
| | - P Alonso
- University Clinical Hospital of Salamanca, Paseo San Vicente 182, Salamanca, 37007, Spain.
| | - F J Serrano
- Dpt. Computers and Automation, University of Salamanca, Plaza de los Caídos S/N, Salamanca, 37008, Spain.
| | - F J Blanco
- Dpt. Computers and Automation, University of Salamanca, Plaza de los Caídos S/N, Salamanca, 37008, Spain.
| |
Collapse
|
2
|
Lorenzo-Gómez I, Nogueira-Recalde U, García-Domínguez C, Oreiro N, Lotz M, Pinto-Tasende JA, Blanco FJ, Caramés B. Defective chaperone-mediated autophagy is a hallmark of joint disease in patients with knee osteoarthritis. Osteoarthritis Cartilage 2023:S1063-4584(23)00700-8. [PMID: 36893980 DOI: 10.1016/j.joca.2023.02.076] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 02/07/2023] [Accepted: 02/10/2023] [Indexed: 03/11/2023]
Abstract
OBJECTIVE Defects in autophagy contribute to joint aging and Osteoarthritis (OA). Identifying specific autophagy types could be useful for developing novel treatments for OA. DESIGN An autophagy-related gene array was performed in blood from non-OA and knee OA subjects from the Prospective Cohort of A Coruña (PROCOAC). The differential expression of candidate genes was confirmed in blood and knee cartilage and a regression analysis was performed adjusting for age and BMI. HSP90A, a chaperone mediated autophagy (CMA) marker was validated in human knee joint tissues, as well as, in mice with aging-related and surgically-induced OA. The consequences of HSP90AA1 deficiency were evaluated on OA pathogenesis. Finally, the contribution of CMA to homeostasis was studied by assessing the capacity to restore proteostasis upon ATG5-mediated macroautophagy deficiency and genetic HSP90AA1 overexpression. RESULTS 16 autophagy-related genes were significantly down-regulated in blood from knee OA subjects. Validation studies showed that HSP90AA1 was down-regulated in blood and human OA cartilage and correlated with risk incidence of OA. Moreover, HSP90A was reduced in human OA joints tissues and with aging and OA in mice. HSP90AA1 knockdown was linked to defective macroautophagy, inflammation, oxidative stress, senescence and apoptosis. However, macroautophagy deficiency increased CMA, highlighting the CMA-macroautophagy crosstalk. Remarkably, CMA activation was sufficient to protect chondrocytes from damage. CONCLUSIONS We show that HSP90A is a key chaperone for chondrocyte homeostasis, while defective CMA contributes to joint damage. We propose that CMA deficiency is a relevant disease mechanism and could represent a therapeutic target for OA.
Collapse
Affiliation(s)
- I Lorenzo-Gómez
- Unidad de Biología del Cartílago, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain
| | - U Nogueira-Recalde
- Unidad de Biología del Cartílago, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain
| | - C García-Domínguez
- Unidad de Biología del Cartílago, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain
| | - N Oreiro
- Unidad de Reumatología Clínica, GIR, CHUAC, Sergas, A Coruña, Spain
| | - M Lotz
- Department of Molecular Medicine, Scripps Research, La Jolla, CA, USA
| | | | - F J Blanco
- Unidad de Biología del Cartílago, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain; Unidad de Reumatología Clínica, GIR, CHUAC, Sergas, A Coruña, Spain
| | - B Caramés
- Unidad de Biología del Cartílago, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain.
| |
Collapse
|
3
|
Wirth W, Maschek S, Marijnissen ACA, Lalande A, Blanco FJ, Berenbaum F, van de Stadt LA, Kloppenburg M, Haugen IK, Ladel CH, Bacardit J, Wisser A, Eckstein F, Roemer FW, Lafeber FPJG, Weinans HH, Jansen M. Test-retest precision and longitudinal cartilage thickness loss in the IMI-APPROACH cohort. Osteoarthritis Cartilage 2023; 31:238-248. [PMID: 36336198 DOI: 10.1016/j.joca.2022.10.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 09/22/2022] [Accepted: 10/30/2022] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To investigate the test-retest precision and to report the longitudinal change in cartilage thickness, the percentage of knees with progression and the predictive value of the machine-learning-estimated structural progression score (s-score) for cartilage thickness loss in the IMI-APPROACH cohort - an exploratory, 5-center, 2-year prospective follow-up cohort. DESIGN Quantitative cartilage morphology at baseline and at least one follow-up visit was available for 270 of the 297 IMI-APPROACH participants (78% females, age: 66.4 ± 7.1 years, body mass index (BMI): 28.1 ± 5.3 kg/m2, 55% with radiographic knee osteoarthritis (OA)) from 1.5T or 3T MRI. Test-retest precision (root mean square coefficient of variation) was assessed from 34 participants. To define progressor knees, smallest detectable change (SDC) thresholds were computed from 11 participants with longitudinal test-retest scans. Binary logistic regression was used to evaluate the odds of progression in femorotibial cartilage thickness (threshold: -211 μm) for the quartile with the highest vs the quartile with the lowest s-scores. RESULTS The test-retest precision was 69 μm for the entire femorotibial joint. Over 24 months, mean cartilage thickness loss in the entire femorotibial joint reached -174 μm (95% CI: [-207, -141] μm, 32.7% with progression). The s-score was not associated with 24-month progression rates by MRI (OR: 1.30, 95% CI: [0.52, 3.28]). CONCLUSION IMI-APPROACH successfully enrolled participants with substantial cartilage thickness loss, although the machine-learning-estimated s-score was not observed to be predictive of cartilage thickness loss. IMI-APPROACH data will be used in subsequent analyses to evaluate the impact of clinical, imaging, biomechanical and biochemical biomarkers on cartilage thickness loss and to refine the machine-learning-based s-score. CLINICALTRIALS GOV IDENTIFICATION NCT03883568.
Collapse
Affiliation(s)
- W Wirth
- Department of Imaging & Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria; Ludwig Boltzmann Inst. for Arthritis and Rehabilitation, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria; Chondrometrics GmbH, Freilassing, Germany.
| | - S Maschek
- Department of Imaging & Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria; Chondrometrics GmbH, Freilassing, Germany.
| | - A C A Marijnissen
- University Medical Center Utrecht and Utrecht University, Utrecht, the Netherlands.
| | - A Lalande
- Institut de Recherches Internationales Servier, Suresnes, France.
| | - F J Blanco
- Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS. Centro de Investigación CICA, Departamento de Fisioterapia y Medicina, Universidad de A Coruña, A Coruña, Spain.
| | - F Berenbaum
- Department of Rheumatology, AP-HP Saint-Antoine Hospital, Paris, France; INSERM, Sorbonne University, Paris, France.
| | - L A van de Stadt
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
| | - M Kloppenburg
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
| | - I K Haugen
- Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
| | - C H Ladel
- CHL4special consultancy, Darmstadt, Germany.
| | - J Bacardit
- School of Computing, Newcastle University, Newcastle, United Kingdom.
| | - A Wisser
- Department of Imaging & Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria; Ludwig Boltzmann Inst. for Arthritis and Rehabilitation, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria; Chondrometrics GmbH, Freilassing, Germany.
| | - F Eckstein
- Department of Imaging & Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria; Ludwig Boltzmann Inst. for Arthritis and Rehabilitation, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria; Chondrometrics GmbH, Freilassing, Germany.
| | - F W Roemer
- Quantitative Imaging Center, Department of Radiology, Boston University School of Medicine, Boston, MA, USA; Department of Radiology, Universitätsklinikum Erlangen and Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
| | - F P J G Lafeber
- University Medical Center Utrecht and Utrecht University, Utrecht, the Netherlands.
| | - H H Weinans
- University Medical Center Utrecht and Utrecht University, Utrecht, the Netherlands.
| | - M Jansen
- University Medical Center Utrecht and Utrecht University, Utrecht, the Netherlands.
| |
Collapse
|
4
|
Loef M, van de Stadt L, Böhringer S, Bay-Jensen AC, Mobasheri A, Larkin J, Lafeber FPJG, Blanco FJ, Haugen IK, Berenbaum F, Giera M, Ioan-Facsinay A, Kloppenburg M. The association of the lipid profile with knee and hand osteoarthritis severity: the IMI-APPROACH cohort. Osteoarthritis Cartilage 2022; 30:1062-1069. [PMID: 35644463 DOI: 10.1016/j.joca.2022.05.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 05/16/2022] [Accepted: 05/18/2022] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To investigate the association of the lipidomic profile with osteoarthritis (OA) severity, considering the outcomes radiographic knee and hand OA, pain and function. DESIGN We used baseline data from the Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH) cohort, comprising persons with knee OA fulfilling the clinical American College of Rheumatology classification criteria. Radiographic knee and hand OA severity was quantified with Kellgren-Lawrence sum scores. Knee and hand pain and function were assessed with validated questionnaires. We quantified fasted plasma higher order lipids and oxylipins with liquid chromatography with tandem mass spectrometry (LC-MS/MS)-based platforms. Using penalised linear regression, we assessed the variance in OA severity explained by lipidomics, with adjustment for clinical covariates (age, sex, body mass index (BMI) and lipid lowering medication), measurement batch and clinical centre. RESULTS In 216 participants (mean age 66 years, mean BMI 27.3 kg/m2, 75% women) we quantified 603 higher order lipids (triacylglycerols, diacylglycerols, cholesteryl esters, ceramides, free fatty acids, sphingomyelins, phospholipids) and 28 oxylipins. Lipidomics explained 3% and 2% of the variance in radiographic knee and hand OA severity, respectively. Lipids were not associated with knee pain or function. Lipidomics accounted for 12% and 6% of variance in hand pain and function, respectively. The investigated OA severity outcomes were associated with the lipidomic fraction of bound and free arachidonic acid, bound palmitoleic acid, oleic acid, linoleic acid and docosapentaenoic acid. CONCLUSIONS Within the APPROACH cohort lipidomics explained a minor portion of the variation in OA severity, which was most evident for the outcome hand pain. Our results suggest that eicosanoids may be involved in OA severity.
Collapse
Affiliation(s)
- M Loef
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
| | - L van de Stadt
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
| | - S Böhringer
- Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands.
| | - A-C Bay-Jensen
- Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.
| | - A Mobasheri
- Regenerative Medicine, State Research Institute Center of Innovative Medicine, Vilnius, Lithuania.
| | - J Larkin
- GlaxoSmithKline USA, Philadelphia, PA, USA.
| | - F P J G Lafeber
- Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, the Netherlands.
| | - F J Blanco
- Servicio de Reumatologia, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain.
| | - I K Haugen
- Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
| | - F Berenbaum
- Rheumatology, Sorbonne University, INSERM, AP-HP Saint-Antoine Hospital, Paris, France.
| | - M Giera
- Center of Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
| | - A Ioan-Facsinay
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
| | - M Kloppenburg
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
| |
Collapse
|
5
|
Ruiz-Romero C, Önnerfjord P, Calamia V, Fernández Puente P, Lourido L, Paz González R, Widera P, Bacardit J, Bay-Jensen AC, Berenbaum F, Haugen IK, Kloppenburg M, Mastbergen S, Larkin J, Mobasheri A, Blanco FJ. OP0224 DISCOVERY PROTEOMICS ANALYSIS IN THE IMI-APPROACH COHORT SHOWS THE DIFFERENTIAL MODULATION AT 24 MONTHS OF PROTEIN PROFILES ASSOCIATED WITH STRUCTURAL OR PAIN PROGRESSION IN OSTEOARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe characterization of differential molecular endotypes in osteoarthritis (OA) is essential for enabling patient stratification to enhance clinical trials, facilitate the development of targeted and individualized treatments.ObjectivesThis study aimed to characterize the profile and dynamics over 24 months (24M) of proteins present in the sera from patients in the IMI-Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH) cohort who exhibited structural (radiographic) and pain progression compared to participants who did not progressed during this period.MethodsForty-five patients enrolled in the IMI-APPROACH cohort were selected for the proteomic analysis. Among these, 15 showed the highest structural progression (group S) and 15 the highest pain progression (group P) at 24M, according to the APPROACH criteria [1], while 15 did not progressed neither in S nor in P. Baseline (BL) and 24M serum samples were depleted of the top 14 most abundant proteins and then analysed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) on a nanoElute-LC coupled to a high-resolution TIMS-QTOF (timsTOF Pro, Bruker Daltonics). Proteins were identified and quantified using the LFQ algorithm of MaxQuant software. Further statistical and bioinformatic analyses were performed using Perseus and OmicsAnalyst software.ResultsThe proteomic analysis resulted in the identification of 558 proteins (10,466 peptides) in the serum samples. A label-free quantification algorithm was employed to quantify 468 proteins in the samples. Hierarchical clustering of the data showed the differences in protein abundance were more relevant longitudinally (BL to 24M) than in cross-sectional comparisons between the three groups under study (N, P or S). Sixty-three proteins were significantly altered (fold change >=1.5, p<0.05) when comparing BL to 24M in the N group (15 increased and 48 decreased), 53 in the P group (20 increased and 33 decreased) and 93 in the S group (19 increased and 74 decreased). Interestingly, two different endotypes were detected at baseline in the N and S groups, based on these protein modulations.The overlapping of these proteomic profiles was analyzed between groups and is shown in the Figure 1. Proteins modulated specifically in the N group may be associated with mechanisms related with joint repair. On the other hand, six proteins (including two apolipoproteins) were increased at 24M only in the P group. Finally, 30 proteins were modulated only in the S group: five of them increased and 25 decreased. Remarkably, this latter group includes lubricin, chaperones and proteins related with proteoglycan binding, such as COMP, fibronectin or histidine-rich glycoprotein.Figure 1.Circulating proteins identified as modulated after 24M follow-up in 45 patients from the APPROACH cohort that progressed in structure (S group; n=15), pain (P group; n=15) or did not progressed (N group; n=15). The numbers with arrows indicate those proteins that decrease (arrow pointing down) or increase (arrow pointing up) compared to baseline.ConclusionThe modulation of specific protein profiles in serum were identified as associated with the progression in structure, pain or non-progression in patients from the APPROACH cohort. Proteomic changes found specifically in the S group may be interesting circulating markers of the structural affectation occurring in the joint.References[1]van Helvoort EM, et al., BMJ Open. 2020 Jul 28;10(7):e035101. doi: 10.1136/bmjopen-2019-035101.Disclosure of InterestsCristina Ruiz-Romero: None declared, Patrik Önnerfjord: None declared, Valentina Calamia: None declared, Patricia Fernández Puente: None declared, Lucía Lourido: None declared, Rocío Paz González: None declared, Pawel Widera: None declared, Jaume Bacardit: None declared, Anne-Christine Bay-Jensen Shareholder of: Nordic Bioscience, Employee of: Nordic Bioscience, Francis Berenbaum Consultant of: AstraZeneca, Boehringer, Bone Therapeutics, CellProthera, Expanscience, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, Merck Sereno, MSD, Nordic, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, 4P Pharma, 4Moving Biotech, Grant/research support from: TRB Chemedica, Ida K. Haugen Consultant of: Abbvie and Novartis, Grant/research support from: Pfizer, Margreet Kloppenburg Consultant of: Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR, Novartis, UCB, Simon Mastbergen: None declared, Jonathan Larkin Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, Ali Mobasheri Consultant of: Merck KGaA, Kolon TissueGene, Pfizer Inc., Galapagos-Servier, Image Analysis Group (IAG), Artialis SA, Aché Laboratórios Farmacêuticos, AbbVie, Guidepoint Global, Alphasights, Science Branding Communications, GSK, Flexion Therapeutics, Pacira Biosciences, Sterifarma, Bioiberica, SANOFI, Genacol, Kolon Life Science, BRASIT/BRASOS, GEOS, MCI Group, Alcimed, Abbot, Laboratoires Expansciences, SPRIM Communications, Frontiers Media and University Health Network (UHN) Toronto, Grant/research support from: Merck KGaA, Kolon TissueGene, Pfizer Inc., Galapagos-Servier, Image Analysis Group (IAG), Artialis SA, Aché Laboratórios Farmacêuticos, AbbVie, Guidepoint Global, Alphasights, Science Branding Communications, GSK, Flexion Therapeutics, Pacira Biosciences, Sterifarma, Bioiberica, SANOFI, Genacol, Kolon Life Science, BRASIT/BRASOS, GEOS, MCI Group, Alcimed, Abbot, Laboratoires Expansciences, SPRIM Communications, Frontiers Media and University Health Network (UHN) Toronto, Francisco J. Blanco Consultant of: Gedeon Richter Plc., Bristol-Myers Squibb International Corporation (BMSIC), Sun Pharma Global FZE, Celgene Corporation, Janssen Cilag International N.V, Janssen Research & Development, Viela Bio, Inc., Astrazeneca AB, UCB BIOSCIENCES GMBH, UCB BIOPHARMA SPRL, AbbVie Deutschland GmbH & Co.KG, Merck KGaA, Amgen, Inc., Novartis Farmacéutica, S.A., Boehringer Ingelheim España, S.A, CSL Behring, LLC, Glaxosmithkline Research & Development Limited, Pfizer Inc, Lilly S.A., Corbus Pharmaceuticals Inc., Biohope Scientific Solutions for Human Health S.L., Centrexion Therapeutics Corp., Sanofi, TEDEC-MEIJI FARMA S.A., Kiniksa Pharmaceuticals, Ltd., Fundación para la Investigación Biomédica Del Hospital Clínico San Carlos, Grünenthal and Galapagos, Grant/research support from: Pfizer
Collapse
|
6
|
Lourido L, Quaranta P, Paz González R, Calamia V, Cañete JDD, Fernandez B, González-Álvaro I, Gonzalez A, Pablos JL, Blanco FJ, Ruiz-Romero C. POS0438 IDENTIFICATION OF ANTI-CYTOKINE AUTOANTIBODIES WITH POTENTIAL TO PREDICT FLARE IN RHEUMATOID ARTHRITIS PATIENTS UNDERGOING BIOLOGICAL THERAPIES: A DISCOVERY STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThe presence of anti-cytokine autoantibodies (ACAAs) seems to be a physiologic mechanism to control the immune response and regulate cytokine activity. Biological therapies also regulate cytokine activities and have greatly improved the quality of life of RA patients. However, alteration of the cytokine network by the use of these treatments may lead to a disbalance in the regulatory system of ACAAs. We hypothesize the ACAAs network may influence the course of immune response in RA patients and may be useful to predict the therapy efficacy.ObjectivesWe aimed to explore the potential of circulating ACAAs to predict flare in a cohort of RA patients treated with biological therapy.MethodsWe employed sera at baseline from 194 RA patients of the clinical trial OPTIBIO1 (A Coruña), whose primary endpoint is to evaluate the usefulness of standardized protocol strategies of dose reduction in patients with RA in clinical remission treated with biologics. These patients were treated with TNF inhibitors (Etanercept, N=47; Infliximab, N=12; Adalimumab, N=35; Certolizumab (CTZ), N=17; Golimumab, N=5), Tocilizumab (TCZ, N=60) and Abatacept (ABA, N=18). Patients were in clinical remission (DAS 28 <2.6 or SDAI <5 or ACR/EULAR 2011 criteria) at least from 6 months. Patients were followed during a minimum period of one year and maximum period of 3 years. Flare was considered when remission criteria were not fulfilled. The bead-based antigen array MILLIPLEX MAP Human Cytokine Autoantibody Magnetic Bead Panel was used for the simultaneous detection and quantification in sera of anti-BAFF, anti-G-CSF, anti-IFNβ, anti-IFNγ, anti-IL-1α, anti-IL-6, anti-IL-8, anti-IL-10, anti-IL-12 (p40), anti-IL-15, anti-IL-17A, anti-IL-17F, anti-IL-18, anti-IL-22, and anti-TNFα. Non-parametrical tests, ROC curves and logistic regressions were performed for the statistical data analysis using SPSS. P-value < 0.05 was considered statistically significant.ResultsThe levels of anti-17A and anti-IL-1α were increased in the sera from patients who suffered a flare during the follow-up period (N= 76), compared to those who remained in remission (N= 118), showing an area under the curve (AUC) of 0.586 and 0.594, respectively. Segregating by treatment, the levels of anti-17A were specifically increased in those relapsing patients under CTZ (N=6), ABA (N=12) and TCZ (N=20) treatment. The AUC of anti-17A within these three therapies was 0.867, 0.903 and 0.682, respectively. Logistic regression analysis also associated the levels of anti-17A with the risk of suffering a flare in TCZ-treated patients (OR=1.11; p=0.015, for 100 MFI increase). In addition, the TCZ-treated patients who suffered a flare also showed higher levels of anti-IL17F, anti-IL-1α, and anti-IL-18 compared to those that remained in remission, showing AUCs of 0.689, 0.657 and 0.698, respectively. Anti-IL-18 was also associated with the risk of flare in these patients (OR=1.65; p=0.028, for 100 MFI increase). The presence of these three ACAAs was also higher in the TCZ-treated patients who suffered a flare compared to those in remission.ConclusionAlthough further validation of our results is needed, we present a ground-breaking study showing the potential of anti-IL17A, anti-IL-1α, and anti-IL18 to predict flare in RA patients under biological therapies.References[1]Bejerano C, et al. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with RA in clinical remission treated with biologic therapies. The Optibio Study. Arthritis Rheumatol. 2016; 68 (suppl 10): 649.Table 1.Table showing a summary of the results. CI: confidence interval• Treatments• ACAAs• AUC (CI 95%; p)Allanti-IL17A0.586 (0.504-0.668; 0.044)anti-IL-1α0.594 (0.512-0.676; 0.028)CTZanti-IL17A0.867 (0.675,1.000; 0.017)ABAanti-IL17A0.903 (0.761-1.000; 0.007)TCZanti-IL-1α0.657 (0.494-0.820; 0.049)anti-IL-17F0.689 (0.551-0.827; 0.018)anti-IL17A0.682 (0.528-0.835; 0.023)anti-IL180.698 (0.545-0.850; 0.013)Disclosure of InterestsNone declared.
Collapse
|
7
|
Rocha B, Cillero-Pastor B, Illiano A, Calamia V, Fernández Puente P, Lourido L, Paz González R, Quaranta P, Celis R, Cuervo A, Pinto G, Amoresano A, Cañete JDD, Heeren RMA, Ruiz-Romero C, Blanco FJ. POS0464 DIFFERENTIAL MOLECULAR PROFILES IN THE SYNOVIAL TISSUE AND SYNOVIAL FLUID OF PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThe differential diagnosis of Rheumatoid Arthritis (RA) and Psoriatic arthritis (PsA) is often difficult due to the similarity of symptoms and the unavailability of reliable clinical biomarkers. Molecular alterations have been suggested to contribute to the pathophysiological processes in the knee joint, and it is known that chronic inflammation induces significant changes in the synovial tissue (ST) and synovial fluid (SF) lipidome and proteome.ObjectivesWe aimed to evaluate whether specific characteristics in the molecular profiles from ST and SF could support the differential diagnosis of these diseases.MethodsST frozen samples of patients affected by RA (n=6), PsA (n=12) and control donors (n=10) were compared using Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging (MALDI-MSI) for spatially resolved lipid analysis. To this end, tissue sections were measured on a RapifleX MALDI-TOF/TOF instrument. Next, a targeted approach based on multiple reaction monitoring (MRM-MS) was performed to further validate the lipidomic alterations reported by MALDI-MSI between RA and PsA tissues. In this case, lipids extracted from SF (control donors (n=4), RA (n=21) and PsA (n=27)) were analyzed in a QTRAP 4000 mass spectrometer for the targeted analysis of 84 lipid species. Finally, a quantitative proteomic analysis was carried out on FFPE ST from RA (n=13), PsA (n=13) and controls (n=8) by nLC-MS/MS analysis using a TimsTOF Pro system (Bruker). Statistical analyses were performed using GraphPad Prism, Metaboanalyst and Perseus software.ResultsLipid profiles in ST from PsA and RA were unequivocally distinguished by MALDI-MSI followed by PCA-DA, and were also different comparing with control tissues. Interestingly, several lipid species, including sphingomyelins, phosphatidylcholines (PC) and phosphatidylethanolamines (PE), presented the greatest separation power to classify RA and PsA tissue samples. ANOVA analysis found 35 lipid species significantly different among the study groups, most of them significantly increased in RA and PsA compared to controls. Particularly, 11 lipids showed higher levels in PsA tissues compared with RA, including several PC and PE. The spatial distribution of these PE species was associated with areas of the sublining layer with increased vascularity and inflammatory cell infiltrates, according to MALDI-MSI images. On the other hand, RA and PsA patients were also correctly classified based on the SF levels of all quantified lipid species according to PCA and clustering analysis. Finally, the proteomic analysis quantified around 2,500 distinct proteins in the ST, including several related with lipid metabolism. Near 300 proteins showed altered abundance in the pathological tissues compared to healthy controls (FDR 0.01%, Figure 1A), being the small subset increased in controls mainly extracellular matrix proteins. The comparison between RA and PsA ST led to the identification of a panel of 36 proteins discriminating the two tissues with high statistical significance (p-value <0.01). In this comparison, all proteins except two appeared increased in RA (Figure 1B). A discriminant analysis shows the usefulness of this protein panel to differentiate the two diseases (Figure 1C).Figure 1.Results from the proteomic analysis carried out on synovial tissues. A) Heatmap showing the differential protein profiles between synovial tissues (PsA and RA) and healthy controls (CTL), at FDR 0.01. B) Characteristic protein panel discriminating PsA and RA tissues (p-value < 0.01). C) Discriminant analysis performed using this protein panel.ConclusionOur study shows distinct molecular profiles between RA and PsA synovial tissue and synovial fluid, and reports potential clinically useful lipid and protein markers for the differential diagnosis of these diseases.Disclosure of InterestsNone declared.
Collapse
|
8
|
Lorenzo I, Nogueira-Recalde U, Garcia-Dominguez C, Oreiro N, Pinto Tasende JA, Lotz M, Blanco FJ, Carames B. POS0226 DEFICIENT CHAPERONE-MEDIATED AUTOPHAGY CONTRIBUTES TO JOINT DAMAGE IN OSTEOARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundIn Osteoarthritis (OA), defects in macroautophagy are evident and precede joint damage. Indeed, pharmacological activation of macroautophagy protects against joint damage and disease.ObjectivesTherefore, identifying hallmarks associated with specific autophagy subtypes could shed light to fundamental mechanisms of joint disease and facilitate the development of therapeutic strategies to prevent OA progression.MethodsA gene expression analysis of 35 autophagy genes was performed from blood from a Prospective OA Cohort of A Coruña (PROCOAC) of non-OA (Age:61,44±1,16 years; BMI:25,25±0,52; Females, n=18) and knee OA subjects (Age:65,50±1,05 years; BMI:29,55±0,67; Females, n=18, OA grade III-IV) by using SYBR green array. The differential expression of candidate genes in blood (n=30/group) and knee cartilage (Non-OA, n=12; Knee OA donors, n=21) was confirmed by using Taqman Technology. HSP90AA1, a chaperone mediated autophagy (CMA) mediator, was evaluated in human knee joint tissues (i.e. cartilage, meniscus, ACL and synovium) with different KL grades (0, 2 and 4, n=3/each KL grade) and in both spontaneous aging mice (2, 6, 12, 18, and 30 months old, n=3/each time) and surgically-induced OA mice (10 weeks after surgery, n=4/each) by immunohistochemistry. The functional consequences of HSP90AA1 deficiency on inflammation, oxidative stress, senescence and apoptosis were studied in human OA chondrocytes by gene and protein expression and flow cytometry. The potential contribution of CMA to chondrocyte homeostasis was studied by assessing the capacity of CMA to restore proteostasis upon macroautophagy deficiency by ATG5 knockdown. To study the therapeutic potential of targeting CMA, HSP90AA1 was overexpressed in human OA chondrocytes.Results16 autophagy-related genes were significantly downregulated in knee OA subjects (p<0.05). Macroautophagy-related genes ATG16L2, ATG12, ATG4B and MAP1LC3B, were significantly downregulated (p<0.05). Interestingly, HSP90AA1 and HSPA8, CMA mediators involved in stress response and protein folding, were significantly downregulated (p<0.001). Confirmatory studies showed a downregulation of MAP1LC3B and HSP90AA1 in blood (p<0.001) and cartilage (p<0.05) from knee OA subjects. Moreover, HSP90A was reduced in human joint tissues (i.e. cartilage, meniscus, ACL, p<0.05) and associated to OA severity. In mice, HSP90A reduction was observed not only in OA (p<0.05) but also in aging (p<0.01). LAMP2A, a key CMA mediator, was also reduced in human OA cartilage and associated with aging in mice (p<0.05). Remarkably, HSP90AA1 deficiency was functionally linked to inflammation, oxidative stress, senescence and apoptosis (p<0.05). Moreover, LAMP2A activity was decreased upon HSP90AA1 deficiency, while mTOR signaling pathway, p62 and active caspase 3 were increased (p<0.05), indicating a failure in the autophagy flux that may lead to impaired lysosomal degradation and apoptosis. Human OA chondrocytes with impaired macroautophagy through ATG5 knockdown show reduced LC3II expression and induced activation of prbs6, p16 and p21 (p<0.05). Interestingly, HSP90A was increased, suggesting a compensatory activation of CMA in response to specific macroautophagy defects. Remarkably, HSP90AA1 overexpression itself is sufficient to protect against joint damage by decreasing mTOR signaling and senescence in human OA chondrocytes.ConclusionTaking together, we identified HSP90A, a marker of CMA, as a key regulator of chondrocyte homeostasis underlying a relevant mechanism in OA. A better definition of the cross-talk between CMA and macroautophagy defects might reveal its role as a hallmark of OA.References[1]Caramés B, et al. Arthritis Rheum. 2010, 2015; 2. Caramés B, et al. Ann Rheum Dis. 2012Disclosure of InterestsNone declared
Collapse
|
9
|
Bonakdari H, Pelletier JP, Blanco FJ, Rego-Perez I, Durán-Sotuela A, Aitken D, Jones G, Cicuttini F, Jamshidi A, Abram F, Martel-Pelletier J. POS0231 GENETIC BIOMARKERS, SNP GENES AND mtDNA HAPLOGROUPS, PREDICT OSTEOARTHRITIS STRUCTURAL PROGRESSORS THROUGH THE USE OF SUPERVISED MACHINE LEARNING. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundKnee osteoarthritis is the most prevalent chronic musculoskeletal debilitating disease. Current treatments are only symptomatic and to improve this, we need a robust prediction model to stratify patients at an early stage according to the risk of joint structure disease progression. Some genetic factors, including single nucleotide polymorphism (SNP) genes and mitochondrial (mt)DNA haplogroups/clusters, have been linked to this disease.ObjectivesFor the first time, we aim to determine, by using machine learning, whether some SNP genes and mtDNA haplogroups/clusters alone or combined could predict early knee osteoarthritis structural progressors.MethodsParticipants (901) were first classified for the probability of being structural progressors. Genotyping included SNP genes TP63, FTO, GNL3, DUS4L, GDF5, SUPT3H, MCF2L, TGFA, mtDNA haplogroups H, J, T, Uk, others, and clusters HV, TJ, KU, C-others. They were considered for prediction with major risk factors of osteoarthritis, namely, age and body mass index (BMI). Seven supervised machine learning methodologies were evaluated. The support vector machine was used to generate gender-based models. The best input combination was assessed using sensitivity and synergy analyses. Validation was performed using 10-fold cross-validation as well as an external cohort (TASOAC).ResultsFrom 277 models, two were defined. Both used age and BMI in addition for the first one of the SNP genes TP63, DUS4L, GDF5, FTO with an accuracy of 85.0%; the second profits from the association of mtDNA haplogroups and SNP genes FTO and SUPT3H with 82.5% accuracy. The highest impact was associated with the haplogroup H, the presence of CT alleles for rs8044769 at FTO, and the absence of AA for rs10948172 at SUPT3H. Validation accuracy with the cross-validation (about 95%) and the external cohort (90.5%, 85.7%, respectively) was excellent for both models.ConclusionThis study introduces a novel source of decision support in precision medicine in which, for the first time, two models were developed consisting of i) age, BMI, TP63, DUS4L, GDF5, FTO and ii) the optimum one as it has one less variable: age, BMI, mtDNA haplogroup, FTO, SUPT3H. Such a framework is translational and would be of benefit to patients at risk of structural progressive knee osteoarthritis.AcknowledgementsThe authors would like to thank the Osteoarthritis Initiative (OAI) participants and Coordinating Center for their work in generating the clinical and radiological data of the OAI cohort and for making them publicly available. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. None of the authors are part of the OAI investigator team. Moreover, the authors are also grateful to the TASOAC participants.A special thanks to ArthroLab Inc. for having provided the MRI data used for classifying structural progressors for each individual.Disclosure of InterestsHossein Bonakdari: None declared, Jean-Pierre Pelletier Shareholder of: ArthroLab Inc., Grant/research support from: Work supported in part by the Osteoarthritis Research Unit of the University of Montreal Hospital Research Centre and the Chair in Osteoarthritis from the University of Montreal., Francisco J. Blanco: None declared, Ignacio Rego-Perez: None declared, Alejandro Durán-Sotuela: None declared, Dawn Aitken: None declared, Graeme Jones: None declared, Flavia Cicuttini: None declared, Afshin Jamshidi Grant/research support from: Received a bursary from the Canada First Research Excellence Fund through the TransMedTech Institute in Canada., François Abram Employee of: was an employee of ArthroLab Inc., Johanne Martel-Pelletier Shareholder of: ArthroLab Inc., Grant/research support from: Work supported in part by the Osteoarthritis Research Unit of the University of Montreal Hospital Research Centre and the Chair in Osteoarthritis from the University of Montreal.
Collapse
|
10
|
Lourido L, Balboa-Barreiro V, Ruiz-Romero C, Rego-Pérez I, Camacho-Encina M, Paz-González R, Calamia V, Oreiro N, Nilsson P, Blanco FJ. A clinical model including protein biomarkers predicts radiographic knee osteoarthritis: a prospective study using data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 2021; 29:1147-1154. [PMID: 33933586 DOI: 10.1016/j.joca.2021.04.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 04/01/2021] [Accepted: 04/12/2021] [Indexed: 02/02/2023]
Abstract
OBJECTIVE We aimed to provide a model to predict the prospective development of radiographic KOA (rKOA). METHOD Baseline sera from 333 non-radiographic KOA subjects belonging to OA Initiative (OAI) who developed or not, rKOA during a follow-up period of 96 months were used in this study. The exploratory cohort included 200 subjects, whereas the replication cohort included 133. The levels of inter-alpha trypsin inhibitor heavy chain 1 (ITIH1), complement C3 (C3) and calcyclin (S100A6), identified in previous large proteomic analysis, were analyzed by using sandwich immunoassays on suspension bead arrays. The association of protein levels and clinical covariates with rKOA incidence was assessed by combining logistic regression analysis, Receiver Operating Characteristic (ROC) analysis, Integrated Discrimination Improvement (IDI) analysis and Kaplan-Meier curves. RESULTS Levels of ITIH1, C3 and S100A6 were significantly associated with the prospective development of rKOA, showing an area under the curve (AUC) of 0.713 (0.624-0.802), 0.708 (0.618-0.799) and 0.654 (0.559-0.749), respectively to predict rKOA in the replication cohort. The inclusion of ITIH1 in the clinical model (age, gender, BMI, previous knee injury and WOMAC pain) improved the predictive capacity of the clinical covariates (AUC = 0.754 [0.670-0.838]) producing the model with the highest AUC (0.786 [0.705-0.867]) and the highest IDI index (9%). High levels of ITIH1 were also associated with an earlier onset of the disease. CONCLUSION A clinical model including protein biomarkers that predicts incident rKOA has been developed. Among the tested biomarkers, ITIH1 showed potential to improve the capacity to predict rKOA incidence in clinical practice.
Collapse
Affiliation(s)
- L Lourido
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain
| | - V Balboa-Barreiro
- Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S), Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, Spain
| | - C Ruiz-Romero
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, Spain
| | - I Rego-Pérez
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain
| | - M Camacho-Encina
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain
| | - R Paz-González
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain
| | - V Calamia
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain
| | - N Oreiro
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain
| | - P Nilsson
- Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, SE-100 44 Stockholm, Sweden
| | - F J Blanco
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias de Arriba 84, 15006, A Coruña, Spain; Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S), Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, Spain.
| |
Collapse
|
11
|
Lorenzo I, Nogueira-Recalde U, Oreiro N, Pinto Tasende JA, Lotz M, Blanco FJ, Carames B. POS0375 CHAPERONE-MEDIATED AUTOPHAGY IS A HALLMARK OF JOINT DISEASE IN OSTEOARTHRITIC PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:In Osteoarthritis (OA), defects in macroautophagy (autophagy) are evident and precede joint damage. Indeed, pharmacological activation of autophagy protects against joint damage.Objectives:Therefore, identifying hallmarks associated with specific autophagy subtypes could shed light to fundamental mechanisms of joint disease.Methods:A comparative analysis of 35 autophagy genes was performed from blood from the Prospective OA Cohort of A Coruña (PROCOAC). Non-OA subjects (Age:61,44±1,16 years; BMI:25,25±0,52; Females, n=18) and Knee OA subjects (Age:65,50±1,05 years; BMI:29,55±0,67; Females, n=18, OA grade III-IV) were profiled using an autophagy gene expression array by SYBR green qPCR. Confirmatory studies were performed in blood from Non-OA subjects (Age:60,13±1,12 years; BMI:24,85±0,59; Females; n=30) and Knee-OA subjects (Age:68,4±1,11 years; BMI:29,65±0,55; Females; n=30, OA grade III-IV) by Taqman qPCR. The candidate gene was evaluated in human knee joint tissues (cartilage, meniscus, ligaments, synovium) with different KL grades (Age: KL0=28,3±4,50; KL2=77±6,08; KL4=62,3±3,05, n=3) and in both spontaneous aging (2, 6, 12, 18, and 30 months old, n=3) and surgically-induced OA (10 weeks after surgery, n=4) in mice by IHC. The functional consequences were studied in T/C28a2 and primary human OA chondrocytes. Autophagy, FOXO, Chaperone-mediated autophagy (CMA), inflammation, and cellular senescence were analyzing by gene and protein expression. Moreover, oxidative stress and cell death were evaluated by FACS. The contribution of CMA to chondrocyte homeostasis was evaluated by studying the capacity of CMA to restore proteostasis upon autophagy deficiency by siATG5.Results:15 autophagy-related genes were significantly downregulated in blood from knee OA patients compared to non-OA patients. No significant upregulation was found for any studied gene, although a trend towards upregulation was found in genes involved in the mTOR pathway. Four key autophagy-related genes, including ATG16L2, ATG12, ATG4B and MAP1LC3B were found downregulated in knee OA patients. Interestingly, HSP90AA1 and HSPA8, CMA markers involved in stress response and protein folding, were downregulated. Confirmatory studies showed a significant downregulation of MAP1LC3B and HSP90AA1 in blood from knee OA patients. Remarkably, HSP90A was found reduced in femoral cartilage (medial and lateral), meniscus and ACL. Moreover, this reduction was higher in medial cartilage compared to lateral cartilage and meniscus, while in synovial membrane, HSP90A expression was found increased. This expression signature was dependent on OA grade severity. In addition, we observed a decrease of HSP90A with aging and OA in mice. The functional consequences of HSP90AA1 gene silencing are related to an increase in NFκB, MMP13, and p16 expression. Interestingly, LAMP2A, a key CMA mediator, HSPA8, MAP1LC3B and FoxO1 expression were upregulated in chondrocytes with HSP90AA1 deficiency, which might indicate an early response to maintain homeostasis. On the other hand, LAMP2A protein is decreased upon HSP90AA1 deficiency, while LC3II and p62 were increased, indicating a failure in the autophagy flux that leads to impaired lysosomal degradation.Moreover, p21, p16 and prbS6 were increased upon HSP90AA1 deficiency, besides increasing mitochondrial ROS production and apoptosis. ATG5 silencing blocks autophagy by reducing LC3II and increasing prbs6, p62, p16 and p21. Interestingly, LAMP2A and HSP90A were found increased, indicating a possible compensative activation of CMA in response to autophagy defects. These results support that HSP90A has an important role in chondrocyte homeostasis by participating in the cross-talk between CMA and autophagy.Conclusion:Taking together, we identified HSP90A, a CMA regulator, as critical in chondrocyte homeostasis. These disease mechanisms are relevant in OA and constitute hallmarks potentially useful to prevent OA progression.References:[1]Caramés B, et al. Arthritis Rheum. 2010, 2015;[2]Caramés B, et al. Ann Rheum Dis. 2012.Disclosure of Interests:None declared
Collapse
|
12
|
Gavín C, Moreno F, Blanco FJ, Pablos JL, Caracuel-Ruiz MA, Rosas J, Hernández-Esteban P, Navarro F, Coronel P, Gimeno M. POS0282 EVALUATION OF A NEW HYALURONATE FORMULATION ONE YEAR AFTER SINGLE INJECTION TO PATIENTS WITH SYMPTOMATIC KNEE OSTEOARTHRITIS (SOYA STUDY). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Osteoarthritis (OA) is a leading cause of chronic pain and disability, and its prevalence is expected to increase worldwide (1) being the knee the most affected joint, especially in older adults. Intra-articular hyaluronic acid (HA) could be of particular benefit in OA patients with co-morbidities, and in case of inadequate response to other pharmacological treatments (2). HA has been generally administered in cycles of 3-5 injections, however, due to the pressure on public health systems, the trend is to reduce the number of injections maintaining the duration of effects as longer as possible.Objectives:To assess the effectiveness and safety of a new formulation of HA, up to one year after one single injection to patients in the SOYA (Symptomatic Osteoarthritis one Year Assessment) study.Methods:Patients with Kellgren-Lawrence (KL) grade 2-3 and Visual Analogue Scale (VAS) pain >=40-<80mm were prospectively included to receive a single injection of MPS-HA2%. At 6m a second injection could be offered to selected patients. Primary outcome was reduction of VAS pain in the target knee. VAS for joint pain and WOMAC were recorded at 6 and 12m; Minimally Clinical Important Improvement MCII (>=20% relative change for VAS pain) and patient and investigator assessments (PGA, IGA) (Likert scale 0-4 points) were also estimated. Adverse events were recorded for safety assessment.Results:One hundred and one patients (mean age 68 years, 74% female and 78% with overweight) were included. Mean pain at baseline in the target knee was 63.57mm and 57% were grade 3 KL with a mean evolution of 7.5 years. Table 1 shows the improvement in VAS and WOMAC scores at 6 and 12 months in the mITT population. Similar results were obtained in PP population.Table 1.Changes in VAS and WOMAC scores, expressed as mean valuesSCOREBaseline6 months12 monthsvaluevalue% variation (95% CI)value% variation (95% CI)VAS pain63.5737.59-39.74* (-49.23; -30.25)38.37-37.67* (-47.82; -27.52)WOMACtotal50.1931.88-37.96* (-46.83; -29.09)31.65-36.47* (-46.20; -26.73)pain49.3732.01-32.92* (-43.37; -22.46)31.08-32.07* (-43.19; -20.95)stiffness49.1228.35-35.24** (-53.22; -17.23)28.71-34.08* (-49.30; 18.86)function52.0735.30-33.95* (-43.49; -24.40)35.15-32.71* (-42.80; -22.62)*p-value: 0.0001; **p-value: 0.0002. Student testThe MCII was achieved by 66.3% of patients at 6m and 62.2% at 12m. Regarding PGA mean score was 2.44 at baseline, 1.35 at 6m and 1.46 at 12m (Wilcoxon, p-value <0.05). As for the IGA mean score was 2.29 at baseline, 1.06 at 6m and 1.48 at 12m (Wilcoxon, p-value <0.05).Fourteen patients received a second injection at 6m and 50% of them achieved at 12m a significant and clinically relevant improvement compared to baseline, above the 20% established for the MCII.In total, 12 adverse events (8 patients) were reported, all of them local, non-serious, and of mild-moderate intensity.Conclusion:Viscosupplementation with a single intra-articular injection of MPS-HA2% has proven to be effective and well tolerated up to 12 months after treatment. The re-infiltration of the joint in appropriate cases has proven to be effective in a significant number of patients. The acceptability of the treatment by the patient was optimal.References:[1]Sebbag E, Felten R, Sagez F, et al. The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database. Ann Rheum Dis. 2019 Jun;78(6):844-848.[2]Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63.Disclosure of Interests:Carlos Gavín: None declared, Francisco Moreno: None declared, Francisco J. Blanco: None declared, José Luis Pablos: None declared, Miguel A. Caracuel-Ruiz: None declared, Jose Rosas: None declared, Pablo Hernández-Esteban: None declared, Francisco Navarro: None declared, PILAR CORONEL Employee of: Meiji Pharma Spain, S.A., Mercedes Gimeno Employee of: Employee of Meiji Pharma Spain, S.A.
Collapse
|
13
|
Lourido L, Ruiz-Romero C, Collado L, Hansson M, Klareskog L, Sjöberg R, Pin E, Nilsson P, Blanco FJ. POS0392 PRESENCE OF FOUR SERUM AUTOANTIBODIES ASSOCIATES WITH THE ACPA STATUS IN EARLY RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The presence of anti-citrullinated protein antibodies (ACPAs) is a hallmark of rheumatoid arthritis (RA) that precede the development of the disease by years and is used for its clinical diagnosis. However, there are RA subjects that test negative for ACPA and thus the early diagnosis on these patients may be delayed. Furthermore, the presence or absence of ACPA in RA supports the hypothesis that on these two subsets of patients underlie different pathogenesis and clinical outcomes.Objectives:In this work, we searched for serum autoantibodies useful to assist the early diagnosis of ACPA-seronegative RA and its management.Methods:We profiled the serum autoantibody repertoire of 80 ACPA-seronegative and 80 ACPA-seropositive RA subjects from the Swedish population-based Epidemiological Investigation of RA (EIRA) cohort. A suspension bead array platform built on protein fragments within Human Protein Atlas and selected from an initial untargeted screening using arrays containing 2660 total antigens was employed to identify IgG and IgA serum autoantibodies. A validation phase on antigen suspension bead arrays was carried out on another set of samples from EIRA containing 386 ACPA-seropositive, 358 ACPA-seronegative and 372 randomly selected control subjects of the same age and sex. A sample-specific threshold based on 20 times the median absolute deviation plus the median of all signals was selected to determine the reactivity of samples. The Wilcoxon rank sum test and Fisher’s test were applied for the comparison of autoantibody levels and reactivity frequencies between the groups.Results:Our data revealed four antigens associated with the ACPA status (Table 1). Testis-specific Y-encoded-like protein 4 (TSPYL4) showed significantly higher IgG reactivity frequency in ACPA-seronegative subjects compared to ACPA-seropositive (8% vs. 3%; P<0.05). Significant differences at IgG autoantibody levels (P<0.05) were also observed between ACPA-seronegative subjects and controls for this specific antigen. Significantly higher IgG autoantibody levels (P<0.05) towards another antigen, dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6), were also observed in ACPA-seronegative subjects compared to ACPA-seropositive and controls. In contrast, we found significantly higher IgG autoantibody levels (P<0.05) in ACPA-seropositive individuals compared to ACPA-seronegative and controls towards two antigens, anosmin-1 (ANOS-1) and muscle related coiled-coil protein (MURC). ANOS-1 shows also significantly higher IgG reactivity frequency in ACPA-seropositive individuals compared to ACPA-seronegative and controls (22%, 9% and 6% respectively; P<0.05). Interestingly, three out of the four antigens discovered to be associated with the ACPA status in early RA are highly expressed in lungs and heart, two of the main extraarticular sites affected in RA. No significant differences were observed at IgA levels for any of the antigens analyzed.Table 1.Scheme of the different phases of the study, the features within each phase and the results. The reactivity to four antigens allows to distinguish ACPA-seronegative (ACPA-), ACPA seropositive (ACPA+) and controls.PhasesUntargeteddiscoveryTargeteddiscoveryTargetedvalidationNumber of samples80 ACPA-80 ACPA-358 ACPA-372 Controls80 ACPA+80 ACPA+386 ACPA+Antigen arrayplatformPlanararraysSuspensionbead array 1Suspensionbead array 2Number of antigens26606227Number of candidatebiomarkers6227 4 (TSPYL4,MAP2K6,ANOS1,MURC)Conclusion:Upon further validation in other early RA sample cohorts, our data suggest the measurement of these four autoantibodies may be useful for the early diagnosis of ACPA-seronegative RA and give insight into the pathogenesis of the different RA subsets.Characters from table content including title and footnotes:Disclosure of Interests:None declared
Collapse
|
14
|
Fernandez-Moreno M, Larkins N, Reynolds A, Hermida Gómez T, Blanco FJ. AB0036 APPA (APOCYNIN AND PAEONOL) REDUCES ROS PRODUCTION AND SENESCENCE IN HUMAN ARTICULAR CHONDROCYTES. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Disease modification is not yet possible for osteoarthritis (OA). Mitochondrial ROS and pro-inflammatory cytokines are involved in the pathogenesis of OA and are potential therapeutic targets. APPA, a combination of apocynin (AP) and paeonol (PA), has the potential capacity to modulate synthesis of pro-inflammatory stimuli.Objectives:To investigate the anti-inflammatory effect of APPA in human articular chondrocytes and cartilage.Methods:Tissue and chondrocytes from human OA cartilage were isolated. The effect of APPA on chondrocyte viability was analyzed using MTT. IL-1β 10 ng/mL and LPS 10 ng/mL were used as pro-inflammatory stimuli. ROS production was evaluated by flow cytometry using DCFH-DA and MitoSoxRed. The percentage of senescent cells was evaluated through the quantification of Fluorescein di-β-D-galactopyranoside (FDG) by flow cytometry. The effect of APPA on gene expression of pro-inflammatory cytokines (IL-8 and TNF-α) and enzymes degrading cartilage (MMP-13 and MMP-3) were analyzed in chondrocyte and cartilage by RT-PCR. Quantification of Toluidine Blue (TB) staining in cartilage was performed to evaluate proteoglycans content using software ImageJ/Fiji. Release of Glycosaminoglycan (GAGs) into the supernatant was quantified using BlyscanTM Glycosaminoglycan assay. Statistical analyses were performed with GraphPad Prism v6.Results:Chondrocytes, incubated in presence of APPA 10 µg/mL for 24 h had viability >85%, reduced cytoplasmic ROS (p=0.028) and mitochondrial anion superoxide production induced by LPS 10 ng/mL (p=0.057). Chondrocytes incubated in presence of APPA 10 µg/mL for 2 hours contained significantly fewer senescent cells (p=0.0079). APPA significantly reduced the gene expression induced by IL-1β 10 ng/mL in chondrocytes of IL-8, TNF-α, MMP-13 and MMP-3. Cartilage incubated with APPA 60 and 100 µg/mL for 48 h showed decreased the MMP-3 gene expression induced by IL-1β (p=0.021 and p<0.0001 respectively). Quantification of TB showed that APPA 60 and 100 µg/mL during 48h increased the proteoglycans in intermedial layer, which had been decreased through the incubation with IL-1β (p=0.0018 and p=0.018 respectively). Quantification of release GAGs into the supernatant decreased significantly when the cartilage explants were incubated for 48h in presence of APPA 100 µg/mL (p=0.028).Conclusion:APPA has a clear anti-inflammatory effect on human articular chondrocytes, and could reduce extracellular matrix degradation of cartilage. This could be mediated by the capacity to modulate ROS production and reduce senescence.Disclosure of Interests:Mercedes Fernandez-Moreno: None declared, Nicholas Larkins Shareholder of: I am a shareholder in AKL Research and Development Ltd, Alan Reynolds Shareholder of: I have share options in AKL Research and Development Ltd, Speakers bureau: I have not been a paid speaker for a pharma company - at least not since 2008 whichI think is outside the scope of this, Consultant of: The last time I was a paid consultant was in 2017 when I acted as a consultant for Avillion and Norgine, Employee of: I am also an employee of AKL Research and Development Ltd, Tamara Hermida Gómez: None declared, Francisco J. Blanco Speakers bureau: LillyPfizerSanofiGalapagos, Consultant of: LillyPfizerSanofiGalapagos, Grant/research support from: LillyMSDMerck SeronoPfizerPierre-FabraRocheSanofiServierUCBAbbvieAmgenBioibericaBristol MayerCelgeneCelltrionCellerixGrunenthalGebro PharmaAKL Research and Development Ltd
Collapse
|
15
|
Durán-Sotuela A, Fernandez-Moreno M, Vazquez Mosquera ME, Ramos-Louro P, Dalmao-Fernandez A, Relaño-Fernandez S, Suárez-Ulloa V, Balboa-Barreiro V, Oreiro N, Vázquez García J, Blanco FJ, Rego-Perez I. POS0347 SPECIFIC MITO-NUCLEAR INTERACTIONS AND mt16519C VARIANT AS PREDICTIVE BIOMARKERS FOR THE RAPIDLY PROGRESSIVE OSTEOARTHRITIS OF THE KNEE. DATA FROM THE OSTEOARTHRITIS INITIATIVE. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The early identification of patients with rapid progressive osteoarthritis (RPOA) could allow the implementation of prevention strategies and their inclusion in clinical trials. Polymorphisms in nuclear and mitochondrial DNA (mtDNA) have been associated with OA. Preliminary analyses by our group showed nuclear single nucleotide polymorphism (nSNP) rs12107036 of TP63 as a potential risk factor for RPOA of the knee.Objectives:i) To analyze interactions between mtDNA haplogroups and rs12107036 ii) To apply Next Generation Sequencing (NGS) to discover novel mitochondrial variants to construct predictive models of RPOA of the knee.Methods:1102 Caucasian subjects from the OAI were classified as follows: i) Rapid progressors (N=255), baseline KL grade 0-1 or 2 in at least one knee, that increases up to KL≥ 3 or 4 respectively during 48-month follow-up. ii) Non-rapid progressors (N=847), with the same baseline characteristics as rapid progressors, but with slower or no evolution over time.mtDNA haplogroups and rs12107036 were assigned by mini-sequencing techniques. Novel mtDNA variants were studied by NGS. Statistical analyses included chi-square tests and generalized estimating equations. Relative excess risk due to interaction (RERI) and attributable proportion (AP) were evaluated for the additive interaction between mtDNA clusters and nSNP rs12107036. A nomogram for the estimation of the risk of RPOA was also developed. Analyses were performed using SPSS Statistics v24 and epi.R package included in R software v3.6.3.Results:Chi-square analyses revealed an increased risk of RPOA in patients with the allele G of rs12107036 and mtDNA cluster UK (OR 2,013; p=0,001). An excess of 70,3% of RERI between nSNP rs12107036 and mtDNA clusters was detected, indicating that 47,1% (AP) of the risk is attributable to this interaction, therefore harboring both genetic factors increase the risk of RPOA up to 4,7 times compared to harboring just one. mtDNA sequencing revealed the variant mt16519 overrepresented in rapid-progressors (OR 1,620; p=0,002).Table 1 shows the predictive model for the risk of RPOA. The interaction between the allele G of rs12107036 and mtDNA cluster KU (OR 1,727; p=0,036), in addition to the variant mt16519C (OR 1,690; p=0,003), showed a significant association with the RPOA phenotype regardless of age, BMI, contralateral knee OA, previous injury and WOMAC pain. Image 1 displays the nomogram for predicting risk of RPOA; as an example, a 70 year old male, with a BMI of 28, WOMAC pain score of 10, contralateral OA and presence of both mito-nuclear interaction and mt16519C, has a risk of RPOA of 0,7.Conclusion:mtDNA genetic variants are useful, not only as modulators of the influence of specific nuclear polymorphisms on the risk of developing RPOA, but also as candidate genetic biomarkers of this phenotype.Table 1.Predictive model for the risk of RPOA phenotypeVariablep-valueORmin 95% CIMAX 95% CIClinical and genetic variablesAge<0,001#1,0561,0381,074Female0,1431,2600,9251,718BMI<0,001#1,0651,0301,101Contralateral OA<0,001#1,9271,4132,626Previous Injury<0,001#1,7701,2932,422WOMAC pain0,001#1,0971,0391,159rs12107036 G0,1721,2260,9151,643mt16519 C0,003#1,6901,2022,375mtDNA Clusters$Others0,8030,9210,4821,760TJ0,4821,2090,7122,052UK0,1360,6980,4351,120HVReferencers12107036 G*mtDNA ClusterG * Others0,5020,7890,3951,576G * TJ0,1580,6470,3531,185G * UK0,036#1,7271,0362,881G * HVReference$mtDNA Clusters: haplogroups with a common phylogenetic origin BMI: Body Mass Index; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; OR: Odds Ratio; CI: confidence interval; #: statistical significance declared at P ≤ 0.05, in bold.Image 1.Nomogran for the estimation of the risk of RPOA phenotype. Circles represent the values for the example. Clusters: haplogroups with a common phylogenetic origin BMI: Body Mass Index; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.Disclosure of Interests:None declared
Collapse
|
16
|
Calamia V, Lourido L, Fernández Puente P, Illiano A, Paz González R, Rocha Loureda B, Collado Rodríguez L, Perez-Pampín E, Ruiz-Romero C, Gonzalez A, Blanco FJ. POS0185 IDENTIFICATION AND VALIDATION OF TWO NOVEL SERUM BIOMARKERS ASSOCIATED WITH THE SEROLOGICAL STATUS OF RHEUMATOID ARTHRITIS PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Despite the diagnostic value of Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA), more serological markers are needed in order to improve early diagnosis and treatment response of the Rheumatoid Arthritis (RA) patients. Increased knowledge about how these two major autoreactivities arise is crucial for understanding how RA develops and what mechanisms drive pathogenesis.Objectives:We aimed to investigate, using a proteomic strategy, novel protein biomarkers associated with RF and/or ACPA that might be useful to stratify seropositive and seronegative RA patients.Methods:A shotgun proteomic analysis was performed on 80 sera from the RA cohort of the Rheumatology Unit of the University Hospital of Santiago de Compostela (CHUS). Sera were classified as seropositive or seronegative according to their RF and ACPA values, and were then analyzed employing the iTRAQ labelling technique (Sciex) followed by LC-MALDI-MS/MS analysis (MALDI-TOF). A Multiple Reaction Monitoring (MRM) method was subsequently developed using the Skyline Software for the simultaneous quantification of 26 peptides belonging to ten putative protein biomarkers. The quantitative targeted analysis was performed using peptides with isotope labelled amino acids as internal standards. Serum levels of orosomucoid 1 (ORM1) and haptoglobin (HPT) were measured using commercially available ELISA Kits in the whole RA cohort (n=260) from the Rheumatology Unit of the University Hospital of A Coruña (HUAC).Results:For the initial screening, eighty sera were grouped according to the ACPA/RF status in 4 pools (20 patients/pool). Using an iTRAQ technology-based quantitative proteomic approach, the abundance of eleven proteins was altered in the sera from ACPApos/RFpos, 13 proteins in ACPAneg/RFpos and 12 proteins in ACPApos/RFneg, compared to ACPAneg/RFneg. Vitamin D binding protein (VTDB) was the unique protein that resulted increased in all the comparisons. For the biomarker verification phase, all the samples from the CHUS cohort were analyzed individually (n=80). Using the MRM technology, 26 peptides belonging to ten putative protein biomarkers associated with double positivity were simultaneously quantified. The statistical analysis showed a significant modulation of 9 peptides (belonging to 4 different proteins) in ACPApos/RFpos, 7 peptides (5 proteins) in ACPAneg/RFpos, and 9 peptides (6 proteins) in ACPApos/RFneg compared to ACPAneg/RFneg (p<0.05). Two acute phase reactants (ORM1 and HPT) displayed the same modulation in both screening and verification phases, thus confirming their association with the double positivity. Finally, in the biomarker validation phase, a total of 260 patients from CHUAC were included (Table 1). RA patients were classified as follows: (1) 112 patients (43.1%) were ACPApos/RFpos; (2) 73 patients (28.1%) were ACPAneg/RFneg; (3) 51 patients (19.6%) were ACPAneg/RFpos; and (4) 24 patients (9.2%) were ACPApos/RFneg. Serum levels of ORM1 and HPT (Figure 1), measured by commercial immunoassays, confirmed their increased values in double seropositive patients (p=0,0053 ORM1; p=0,0026 HPT). Finally, the increased level of ORM1 resulted associated with RF rather than ACPA status (p=0,0008 ACPAneg/RFpos); whereas HPT was associated with ACPA rather than RF status (p=0,0112 ACPApos/RFneg).Table 1.The different phases of RA biomarker development followed in this study.DISCOVERYPHASEVERIFICATIONPHASEVALIDATIONPHASESource centerCHUSCHUSCHUACN° ofsamplesn= 4n= 80n= 260ACPA+RF+Pool 1ACPA+RF+20ACPA+RF+112ACPA-RF-Pool 2ACPA-RF-20ACPA-RF-73ACPA-RF+Pool 3ACPA-RF+20ACPA-RF+51ACPA+RF-Pool 4ACPA+RF-20ACPA+RF-24N° ofbiomarkersORM1, ORM2, HPT, A2GL, AACT, RBP4, PLMN, IC1, VDBP, APOBORM1, HPT, A2GL, AACTORM1, HPTFigure 1.Conclusion:The determination of ORM1 and HPT in sera provides novel information useful for patient stratification, which might improve diagnostic and prognostic approaches and facilitate the development of personalized medicine strategies in RA.Acknowledgements:This work is supported by grants from Fondo de Investigación Sanitaria (RD16/0012/0002, PT17/0019/0014) integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research-European Regional Development Fund (FEDER) “A way of making Europe”.Disclosure of Interests:None declared
Collapse
|
17
|
Rocha B, Cillero-Pastor B, Ruiz-Romero C, Paine MRL, Cañete JD, Heeren RMA, Blanco FJ. Identification of a distinct lipidomic profile in the osteoarthritic synovial membrane by mass spectrometry imaging. Osteoarthritis Cartilage 2021; 29:750-761. [PMID: 33582239 DOI: 10.1016/j.joca.2020.12.025] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 11/12/2020] [Accepted: 12/16/2020] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Synovial inflammation is one of the most characteristic events in different types of arthritis, including Osteoarthritis (OA). Emerging evidence also suggests the involvement of lipids in the regulation of inflammatory processes. The aim of this study was to elucidate the heterogeneity and spatial distribution of lipids in the OA synovial membrane and explore their putative involvement in inflammation. METHOD The abundance and distribution of lipids were examined in human synovial membranes. To this end, histological cuts from this tissue were analysed by matrix-assisted laser desorption ionization - mass spectrometry imaging (MALDI-MSI). The lipidomic profile of OA synovium was characterized and compared with healthy and other forms of inflammatory arthropathies as Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) using principal component analysis and discriminant analysis methods. Lipid identification was undertaken by tandem MS analyses and database queries. RESULTS Our results reveal differential and characteristic lipidomic profiles between OA and control samples. Specifically, we unveiled that OA synovium presents elevated levels of phosphatidylcholines, fatty acids and lysophosphatidic acids and lower levels of lysophosphatidylcholines compared to control tissues. The spatial distribution of particular glycerophospholipids was also correlated with hypertrophic, inflamed or vascularized synovial areas. Compared with other inflammatory arthritis, the OA tissue showed lower amounts of phosphatidylethanolamine-based plasmalogens. CONCLUSIONS This study provides a novel insight into the lipid profiles of synovial membrane and differences in abundance between OA and control tissues. The lipidomic alterations improves understanding of the pathogenic mechanisms of OA and may be important for its diagnosis.
Collapse
Affiliation(s)
- B Rocha
- Grupo de Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), C/ As Xubias de Arriba 84, 15006, A Coruña, Spain
| | - B Cillero-Pastor
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, the Netherlands
| | - C Ruiz-Romero
- Grupo de Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), C/ As Xubias de Arriba 84, 15006, A Coruña, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, Spain.
| | - M R L Paine
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, the Netherlands
| | - J D Cañete
- Unidad de Artritis. Servicio de Reumatología. Hospital Clínico de Barcelona, Barcelona, Spain
| | - R M A Heeren
- The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, the Netherlands
| | - F J Blanco
- Grupo de Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), C/ As Xubias de Arriba 84, 15006, A Coruña, Spain; Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S), Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, Spain.
| |
Collapse
|
18
|
Lourido L, Ruiz-Romero C, Picchi F, Diz-Rosales N, Vilaboa-Galán S, Fernández-López C, Pinto Tasende JA, Perez-Pampin E, Regueiro Expósito C, Mera Varela A, Gonzalez A, Hambardzumyan K, Saevarsdottir S, Nilsson P, Blanco FJ. AB0206 CIRCULATING CENTROMERE PROTEIN F AUTOANTIBODIES FOR PREDICTING CLINICAL RESPONSE TO INFLIXIMAB IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:One third of patients with rheumatoid arthritis (RA) respond poorly to TNF inhibitors and related studies are inconsistent in predictive biomarkers. The identification of biomarkers that predict the treatment response prior to drug exposure is a current priority on the RA field. ACPA and RF are ubiquitously tested in RA patients, but other autoantibodies exist and may provide additional information on RA treatment response.Objectives:This study aimed to identify circulating autoantibodies for predicting response to infliximab (IFX) in RA.Methods:We profiled the autoantibody repertoire of baseline sera from 155 biologic naïve RA patients treated with IFX. The sera were provided by three independent clinical sources and distributed in one exploratory cohort (N=20) collected from Hospital Clínico Universitario of Santiago de Compostela (Spain), one replication cohort (N=61) collected from Hospital Universitario de A Coruña (Spain) and samples from the Swedish Farmacotherapy (SWEFOT) trial (Sweden) (N=74) for clinical validation. The presence of autoantibodies and their levels in serum were analysed in association with EULAR clinical response at 6 months follow-up: good response (GR, N=56), moderate (MR, N=55) and non-response (NR, N=44). A suspension bead array platform built on protein fragments within Human Protein Atlas and selected from an initial untargeted screening using an array containing 42000 antigens was employed to identify the IgG and IgA autoantibodies on the exploratory cohort. A replication and validation phases were carried out on the other two serum sample cohorts. Meta-analysis and Receiver Operating Curves were performed in order to assess the clinical relevance of the findings observed.Results:Meta-analysis revealed that the levels in serum of IgG autoantibodies against Centromere protein F (CENPF) are significantly increased in responders (good responders and moderate responders; N=111) to IFX compared to non-responders (N=44) (P=0.018). CENP-F is a proliferation-associated and cell cycle-dependent centromere autoantigen that might be involved in the increased or abnormal cell proliferation that occurs during RA process. The combination of the anti-CENPF antibodies with clinical variables (age, sex, DAS28-ESR) resulted in the best model to discriminate the patients that will respond to IFX, showing an AUC of 0.756 (95% CI [0.639-0.874], P=0.001).Conclusion:High serum levels of IgG anti-CENPF antibodies might be potentially useful to identify RA patients more likely to benefit from IFXDisclosure of Interests:Lucía Lourido: None declared, Cristina Ruiz-Romero: None declared, flor picchi: None declared, Naomi Diz-Rosales: None declared, Sergio Vilaboa-Galán: None declared, Carlos Fernández-López: None declared, Jose Antonio Pinto Tasende: None declared, Eva Perez-Pampin: None declared, Cristina Regueiro Expósito: None declared, ANTONIO MERA VARELA: None declared, Antonio Gonzalez: None declared, Karen Hambardzumyan: None declared, Saedis Saevarsdottir Employee of: Part-time at deCODE Genetics/Amgen Inc, working on genetic research unrelated to this project, Peter Nilsson: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer
Collapse
|
19
|
Durán-Sotuela A, Fernandez-Moreno M, Vazquez Mosquera ME, Ramos-Louro P, Dalmao-Fernandez A, Relaño-Fernandez S, Oreiro N, Blanco FJ, Rego-Perez I. THU0012 IMPACT OF RS12107036 POLYMORPHISM OF TP63 ON THE RISK OF RAPID PROGRESSIVE OSTEOARTHRITIS OF THE KNEE. DATA FROM THE OSTEOARTHRITIS INITIATIVE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:There is a need to identify patients with the rapid progressive phenotype of Osteoarthritis (RPOA) to include them in clinical trials and to implement prevention strategies. During the last years, nuclear single nucleotide polymorphisms (SNPs) were associated with susceptibility and progression of the disease, but not with the rapid progression phenotype.Objectives:Analyze the influence of previously knee OA-associated nuclear SNPs on the risk of RPOA in patients of the OAI.Methods:Caucasian patients from the OAI were selected and assigned into three different groups (N=252/group) based on the following criteria:A.rapid progressors; baseline KL grade 0-1 in at least one knee and increase up to KL≥ 3 during a 48-month period; or baseline KL grade 2 in at least one knee and increase up to KL 4 or total knee replacement during the follow-up.B.no-rapid progressors; baseline KL grade 0-1 in at least one knee and increase up to KL 2 during 48-month period; or baseline KL grade 2 in at least one knee and increase up to KL 3 during the follow-up.C.no-progressors; KL grade 0-2 at baseline in at least one knee and bilaterally stable during 48-month period.Groups were re-categorized into two groups: non-progressors and progressors (pooling A and B). Nuclear SNPs were previously assigned by mini-sequencing techniques. Preliminary chi-square analyses and binary and multinomial logistic regression models adjusted by gender, age, body mass index (BMI), contralateral OA, previous injury in target knee and WOMAC pain, were performed with IBM SPSS Statistics v24.Results:We analyzed the effect of 7 SNPs that had been strongly associated with knee OA susceptibility in different GWAS studies: rs11177, rs4730250, rs11842874, rs12107036, rs8044769, rs10948172 and rs143383. Chi-square analyses only showed differences in the frequency distribution of rs12107036 between groups (p=0,028), being the GG genotype over-represented in the rapid progressors group and the AA genotype in the non-progressors group (Figure 1).The binary logistic regression showed that G allele was significantly over-represented in the (pooled) progressors group when compared with non-progressors (p=0,008) (Table 1). And the multinomial logistic regression showed that, in addition to age and previous injury in target knee, the GG genotype (p=0,032) emerged as a potential risk factor for the RPOA when compared with non-rapid progressors (Table 2).Table 1.Binary regression model comparing progressors pool vs. no-progressVariablesp-valueORC.I. 95%Min.Max.Age0,2171,0120,9931,030Sex (Female)0,000#2,0491,4782,842BMI0,000#1,0851,0441,127Contralateral OA (Yes)0,044#1,4001,0091,942Previous Injury (Yes)0,002#1,7231,2232,429WOMAC pain0,003#1,1021,0331,177rs12107036 G (Yes)0,008#1,6821,1482,463CI: confidence interval; OR: Odd Ratio; #: statistical significance declared at P ≤ 0.05Table 2.Multinomial regression model comparing rapid vs. no-rapid progressors.Variablesp-valueORC.I. 95%Min.Max.Age0,000#1,0641,0411,088Sex (Female)0,4980,8750,5951,287BMI0,0961,0340,9941,077Contralateral OA (Yes)0,7921,0520,7191,539Previous Injury (Yes)0,028#1,5231,0472,216WOMAC pain0,0911,0550,9921,123rs12107036 GG (Yes)0,032#1,5741,0392,382CI: confidence interval; OR: Odd Ratio; #: statistical significance declared at P ≤ 0.05Conclusion:The G allele of the nuclear SNP rs12107036 of TP63 gen increases the risk of knee OA progression. Depending on the number of risk allele copies the level of progression varies, being the GG genotype a risk factor for the RPOA of the knee. The assignment of this nuclear polymorphism could be useful as complementary genetic biomarker for the early identification of this phenotype.Disclosure of Interests:Alejandro Durán-Sotuela: None declared, Mercedes Fernandez-Moreno: None declared, Maria Eugenia Vazquez Mosquera: None declared, Paula Ramos-Louro: None declared, Andrea Dalmao-Fernandez: None declared, Sara Relaño-Fernandez: None declared, Natividad Oreiro: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer, Ignacio Rego-Perez: None declared
Collapse
|
20
|
Sánchez-Pedreira PC, Vela-Anero Á, Otero Queijas N, Lorenzo Toja M, Somaza Serantes A, Hermida Gómez T, Blanco FJ. THU0061 EVALUATION OF SAFETY AND EVOLUTION OF OSTEOARTHRITIC JOINTS AFTER THE ADMINISTRATION OF HETEROLOGOUS MESENCHYMAL STROMAL CELLS IN AN ANIMAL MODEL. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:One of the main osteoarthritis (OA) consequences is the cartilage loss. Nowadays there is not cure for the OA, so there is an intense research focused on finding a therapy to solve this problem. In this paradigm heterologous mesenchymal stromal cells (MSCH) rise as a solution. Different studies used them as a cellular therapy in order to regenerate damaged cartilage. Furthermore, MSCH have shown anti-inflammatory effects.Objectives:1) Study the safety of a single intraarticular injection of MSCH derived from healthy canine fat tissue (adMSCH) in OA joints of dogs2) Observe the evolution of functionality and range of articular mobility of these treated joints 6 months after the injection.Methods:adMSCH obtained (n=10) were phenotypically characterized by flow cytometry, including the Major Histocompatibility Complex type II (MHC-II). Those with the best morphology and growth (n=5) were used for the injection.The infiltrated dogs (n=7) met our inclusion/exclusion criteria. The adMSCH were injected in 11 joints by 1 million of cells/kilogram of weight.Before the infiltration we evaluated the joints (basal visit, BV), the vital signs and the animal pain by the owner (Visual Analogical Scale, VAS). The same data were collected one week after the infiltration (V1) and also studied the injected zone. Six months after treatment (V2), joint functionality and range of articular mobility were evaluated, also data of behavioural changes and pain observed by the owners.Results:All cells obtained were negative for the MHC-II (0.45 ± 0.32).Vital signs did not change between BV and V1. No dog suffered by severe inflammation of the injected joint. One of them during two days had difficulty to support the load in the posterior limbs, but at the third day it performed that without difficulty. Other dog suffered mild inflammation which was solved in two days. The other animals did not show any adverse effect after the infiltration. In the V1 none of them showed any inflammation in the joint. The pain evaluation by the owners showed that all dogs have less pain or it did not increase since BV. This indicate that after the infiltration the animals did not suffer a pain increase.Data collected in V2 showed that the joint functionality tend to improve, one of the items showing significant differences between BV and V2. The range of articular mobility did not have neither differences nor tendencies to the improvement (Table 1).Table 1.Functionality and range of articular mobility comparison between BV and V2. Visits column show the number of joints in that stateVariableAnswersVisitst-student (p-value)nBVV2FUNCTIONALITYLoad changesNormal370.09511Change load84Support fingers00No support00Load changes when getting upCorrectly160.024*11Position modification105Difficulty to get up00No get up00Lameness in coldNo lameness120.06211Mild lameness69Intense lameness40No support00Lameness when warmedNo lameness130.10611Mild lameness88Intense lameness20No support00RANGE OF ARTICULAR MOBILITYArticular passive manual mobilityWithout pain000.40011Mild pain35Raised pain86Disabling pain00Flexion limitationTotal flexion980.75011Mild limitation12Severe limitation11Extension limitationTotal extension030.74911Mild limitation94Severe limitation24*. Statistical significance stablished at P ≤ 0.05Conclusion:The administration of adMSCH did not show adverse effects, rejection, infection or complications, only a probably of a mild inflammation in the treated zone. Also, joint functionality tends to improve, so these cells seem to have, at least, an anti-inflammatory effect into the OA joint.Acknowledgments:Special thanks to the owners of the dogs who participated in this study.Disclosure of Interests:Paula-Catarina Sánchez-Pedreira: None declared, Ángela Vela-Anero: None declared, Nuria Otero Queijas: None declared, María Lorenzo Toja: None declared, Andrés Somaza Serantes: None declared, Tamara Hermida Gómez: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer
Collapse
|
21
|
Camacho Encina M, Balboa-Barreiro V, Rego-Perez I, Paz González R, Calamia V, Lourido L, Ruiz-Romero C, Blanco FJ. FRI0387 A PROGNOSTIC MODEL OF PRE-RADIOGRAPHIC KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4450] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The improvement of the existing diagnostic methods to detect pre-radiographic knee OA (KOA) may facilitate the development of preventive strategies. It has been postulated that combining biochemical with clinical markers, may increase the prognostic power to detect who is at high risk for developing KOA.Objectives:To validate and qualify the ability of 6 proteins with biomarker potential to generate a prognostic model of knee OA prediction through the combination of validated OA biomarkers and clinical markers.Methods:In thevalidation phase(Figure 1), 749 sera at the baseline visit belonging to participants from the Osteoarthritis Initiative (OAI) Cohort were randomly selected to blindly quantify 6 biomarkers using in-house custom sandwich microarrays built using the xMAP technology. Among these, only 540 participants have a Kellgren and Lawrence (KL) grade = 0-1 at the beginning of the OAI study in at least one knee. After a follow-up period of 96 months, 209 participants developed KOA in at least one knee (KL ≥ 2) and were classified as incident group, whereas 331 did not developed the disease (KL = 0-1) and were classified as not-incident group. Statistical differences between the outcome groups were assessed by non-parametric Mann-Whitney U tests. In thequalification phase(n=540), univariate regression analyses were carried out to investigate whether the individual biomarkers were associated with the risk of KOA development. A clinical prognostic model was defined by stepwise regression analysis using clinical non-radiographic variables significantly associated with the OA incidence. The utility of the potential biomarkers, alone or in combination, was evaluated by comparing the Area Under the Curve (AUC) of the clinical prognostic model with the biomarkers plus clinical prognostic models. In addition, senFigure 1.Study desingResults:The incident group showed significant higher serum concentrations at the baseline visit (p < 0.05) for all the potential biomarkers analyzed in this study. Moreover, 5 of them were also significantly associated with the future appearance of radiographic KOA, yielding Odds Ratios (OR) ≥ 10 per 10 µg/ml increase. Among all the possible combinations, the inclusion of 2 biomarkers to the clinical prognostic model showed a significant improvement of the predictive capacity (AUCs = 0.78 vs 0.82, p= 0,044) with 65% (95% Confidence Interval (95%CI): 60-70%) specificity and 88% (95%CI: 81-91%) sensitivity. Variables included in the regression model and all metrics comparing the biomarkers plus clinical prognostic model with the clinical prognostic model are shown in Figure 2A. The ROC curves of the biomarkers-only model, clinical prognostic model and biomarkers plus clinical prognostic model are represented in Figure 2B.Figure 2.(A) Multivariate regression analysis (B) ROC curves of the modelsConclusion:We have generated a prognostic model for the prediction of KOA by combining biomarkers and clinical variables, which showed a putative utility in the clinical setting by improving the predictive capacity of a clinical prognostic model to identify patients at a higher risk to develop radiographic KOA.Disclosure of Interests:Maria Camacho Encina: None declared, Vanesa Balboa-Barreiro: None declared, Ignacio Rego-Perez: None declared, Rocío Paz González: None declared, Valentina Calamia: None declared, Lucía Lourido: None declared, Cristina Ruiz-Romero: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer
Collapse
|
22
|
Mucientes A, Herranz E, Lois P, Blanco FJ, Abasolo L, Rodriguez Rodriguez L, Lamas JR, Fernandez B. AB0077 CONTRIBUTION OF NOTUM TO THE DEVELOPMENT OF OSTEOARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4569] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Osteoarthritis (OA) is a degenerative disease characterized by altered homeostasis of joint cartilage and bone, the functionality of which relies on chondrocytes and osteoblasts, that leads to the formation of a defective extracellular matrix (ECM). The ECM plays an essential role in bone biology as it provides the structure of cartilage which serves as a template for bone formation. Collagen X, main component of the ECM, has been described by our group as down-regulated in OA [1]. Our data also points to an important role of the Wnt pathway in OA [1,2]. Furthermore, Wnt proteins have been reported to inhibit chondrogenesis [3], and the Wnt pathway and its modulators have gained attention [4]. Glypicans (GPC1 to GPC6) and NOTUM, among others, have been identified as modulators of this pathway [5,6]. Notably, due to its highly specific inhibition of the Wnt pathway, NOTUM has been proposed as a therapeutic target in conditions with a high activity of the Wnt pathway is involved, such as OA [7].Objectives:We hypothesize that modulators of the Wnt pathway are involved in the development of OA. The aim of this study is to evaluate the presence of Glypicans and NOTUM in the serum of OA patients and healthy individuals in order to determine whether significant differences exist and could clarify their likely involvement in OA.Methods:Peripheral blood samples were obtained from OA patients during routine rheumatologist hospital visits. OA diagnosis was established according to the ACR criteria. Samples from healthy individuals were obtained from the local Blood Bank. In both cases, blood samples were centrifugated (2000g, 15 minutes, 10°C) and serum was obtained.Quantitative ELISA assays for GPC1-6 and NOTUM were carried out using commercial kits (Human GPC1 ELISA Kit, #E-EL-H1710, Elabscience; Human GPC2 ELISA Kit, #E-EL-H1711, Elabscience; Human GPC3 ELISA Kit, #E-EL-H1712, Elabscience; Human GPC4 ELISA Kit, #E-EL-H1713, Elabscience; Human GPC5 ELISA Kit, #ELH-GPC5, RayBiotech; Human GPC6 ELISA Kit, #CSB-EL009708HU, Cusabio; Human Protein NOTUM homolog ELISA Kit, #EK3787, Sab Biotech) and measured in a plate reader (Heales MB-580,Shenzhen Heales Technology Development Co. Ltd.). Protein concentration in serum was calculated using GraphPad Prism 7 software. Differences between samples were analysed with Mann-Withney U test. Significance level set wasp<0.05.Results:Serum from 40 OA patients and 40 healthy donors were included in the study. There were no differences between groups (Table 1).Table 1.Cohort descriptionControl group (n=40)OA group (n=40)Age66,82±5,7569,59±11,24Women (%)32 (80%)30 (75%)Out of 7 proteins analyzed, only NOTUM showed a significant difference between healthy and OA groups (MedianOA=0.4451ng/mL, MedianCONTROL=0.8263ng/mL,p=0.0013). Besides, GPC4 showed an approaching formal significance (MedianOA=0.1254ng/mL, MedianCONTROL=0.1596ng/mL,p=0.0767). The rest of Glypicans analyzed showed no significance differences between groups (GPC1, MedianOA=0.1346ng/mL, MedianCONTROL=0.1190ng/mL,p=0.2379; GPC2, MedianOA=2.593ng/mL, MedianCONTROL=2.955ng/mL,p=0.7489; GPC3, MedianOA=2.024ng/mL, MedianCONTROL=1.422ng/mL,p=0.3574; GPC5, MedianOA=3.663ng/mL, MedianCONTROL=5.529ng/mL,p=0.8829; GPC6, MedianOA=0.3922ng/mL, MedianCONTROL=0.3558ng/mL,p=0.3212).Conclusion:Our results suggest that low levels of NOTUM may contribute to the development of OA. The lack of this inhibitor promotes the activation of the Wnt pathway, high activity of which has been related with OA.References:[1]Lamas JRet al.Ann Rheum Dis, 2010. 69(10):1880-5.[2]Tornero-Esteban Pet al. PLoS One, 2015. 10(9): p. e0137170.[3]Dayet al. Dev Cell. 2005. 8(5):739-50.[4]Monteagudo S and Lories RJ. Nat Rev Rheumatol, 2017. 13(11): p. 670-681.[6]Li Net al. Trends Cancer. 2018 Nov;4(11):741-754.[7]De Robertis Met al. Oncotarget, 2015. 6(38): p. 41237-57.[8]Nusse R. Nature, 2015. 519(7542): p. 163-4.Disclosure of Interests:Arkaitz Mucientes: None declared, Eva Herranz: None declared, Pia Lois: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer, Lydia Abasolo: None declared, Luis Rodriguez Rodriguez: None declared, José Ramón Lamas: None declared, Benjamin Fernandez: None declared
Collapse
|
23
|
Vaamonde García C, Domínguez H, Blanco FJ, Meijide Failde R. AB0078 ANTI-FIBROTIC EFFECT OF DIFFERENT FUCOIDANS IN OSTEOATHRITIC FIBROBLAST-LIKE-SYNOVIOCYTES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Synovial fibrosis is a pathological process observed in several musculoskeletal disorders that contributes to articular pain and stiffness. It is characterized by the excessive deposition of extracellular matrix, as well as cell migration and proliferation, being TGF-β main inductor of these processes. Fucoidans are sulfated polysaccharide obtained mainly from various species of brown algae and brown seaweed such as Fucus vesiculosus, Undaria pinnatifida, or Macrocystis pyrifera. Recent studies show that fucoidans are promising candidates to address the symptoms of OA. Although a wide spectrum of biological activities has been registered in these polysaccharides, their properties vary between fucoidans from different species.Objectives:Our aim was to evaluate and to compare the anti-fibrotic effects of different fucoidans on fibroblast-like synoviocytes (FLS).Methods:FLS were isolated from OA patients. Primary cultured cells were treated with fucoidans from Fucus vesiculosus (FF), Undaria pinnatifida (FU) and Macrocystis pyrifera (FM) at 5, 30. To activate pro-fibrotic pathways, cells were stimulated with TGF-β and cell viability and proliferation were analyzed by MTT and BrdU assay, respectively. Then gene expression of extracellular matrix proteins, collagen I and III and fibronectin, as well as plod2b, gene coding for alterative splice-variant of lysyl hydroxylases LDH2b, were evaluated by RT-qPCR. The presence of fibrotic maker, alpha smooth muscle actin (α-sma), was analyzed by immunocytochemistry and intracellular collagen levels were assessed by picrosirius red staining. Wound-clousure and transwell cell invasion assay were also performed to evaluate the capacity of cell motility and invasiveness.Figure 1.Measurement of expression of pro-fibrotic markersResults:TGF-β induced a clear pro-fibrotic response (Figure 1). Cell proliferation induced by TGF-β was attenuated in the presence of all tested fucoidans. These polysaccharides also reduced the gene expression of TGF-β-elicited collagen I and III (p< 0.05), although FF failed to downregulate fibronectin levels and none of them showed modulation of plod2b expression. Results were confirmed at protein level. FF30 and FM5 reduced intracellular collagen accumulation induced by TGF-β (p< 0.05). Likewise, the expression of a-sma in TGFb-activated FLS was significantly diminished in the presence of all fucoidans (p< 0.05). By scratch wound assay, we observed that TGF-b induced cell mobility to close the scratch, which was inhibited by all fucoidans. Similarly, FU and FM were also able to attenuated cell invasion after TGF stimulation. Additionally, we also detected that fucoidans showed anti-inflammatory effects in FLS as they reduced the NO production and IL-6 expression induced by IL-1.Conclusion:Our results indicate a protective effect of fucoidans against activated pro-fibrotic pathways in fibroblast-like synoviocytes. However, we detected that these beneficial activities vary between fucoidans from different species and further studies are warranted.Disclosure of Interests:Carlos Vaamonde García: None declared, Herminia Domínguez: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer, Rosa Meijide Failde: None declared
Collapse
|
24
|
Van den Bosch F, Wei JCC, Nash P, Blanco FJ, Graham D, Zang C, Arthur E, Borlenghi C, Vlahos B, Deodhar A. OP0107 ETANERCEPT WITHDRAWAL AND RE-TREATMENT IN PATIENTS WITH INACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AT 24 WEEKS: RESULTS OF RE-EMBARK, AN OPEN-LABEL, PHASE IV TRIAL. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1322] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:In the RE-EMBARK trial (NCT02509026), etanercept (ETN)-treated patients with non-radiographic axial spondyloarthritis (nr-axSpA) who achieved inactive disease (defined as Ankylosing Spondylitis Disease Activity Score with C-reactive protein [ASDAS CRP] <1.3) in Period 1 (P1)1discontinued ETN for ≤40 weeks.Objectives:To assess the proportion of patients with inactive disease after P1 who experienced disease flare (ASDAS with erythrocyte sedimentation rate [ASDAS ESR] ≥2.1) within 40 weeks of ETN withdrawal and to estimate time to flare following ETN withdrawal.Methods:RE-EMBARK was a multicenter, open-label, Phase IV trial of ETN in patients with active nr-axSpA (meeting Assessment in SpondyloArthritis international Society criteria and with ASDAS CRP ≥2.1) and an inadequate response to ≥2 nonsteroidal anti-inflammatory drugs (NSAIDs) while taking a stable dose of 1 NSAID for ≥2 weeks before the first ETN dose. All patients received ETN (50 mg/week) plus NSAID for the first 24 weeks (P1). At week 24, patients with inactive disease discontinued ETN for ≤40 weeks (Period 2 [P2]). Those who experienced flare during P2 were re-treated with ETN for 12 weeks in Period 3 (P3). Kaplan-Meier (KM) analysis and Cox proportional hazard models were used to 1) estimate the probability of experiencing flare within a given time period, and 2) compare data between RE-EMBARK and the EMBARK trial (NCT01258738) of patients with nr-axSpA who met RE-EMBARK P2 entry criteria (achieved inactive disease after 24 weeks of ETN treatment) and continued treatment for a further ≤40 weeks.Results:Of the 209 patients in P1 (mean age, 33 years; women, 46%; white, 89%), 119 (57%) entered P2. The proportion of patients experiencing ≥1 flare increased from 22% (25/112) at P2 week 4 to 67% (77/115) at P2 week 40. Overall, 75% (86/115) of patients in P2 experienced flare and 50% experienced flare within 16 weeks (95% CI: 13-24 weeks, KM analysis). Conversely, data from the comparator EMBARK trial suggested that <25% of patients receiving continuous ETN treatment over 40 weeks experienced flare. Cox proportional hazard model analysis showed an 85% relative risk reduction of experiencing flare during P2 in patients with inactive disease who continued ETN treatment vs those who discontinued. By P3 end 62% (54/87) of patients re-treated with ETN re-achieved inactive disease; 50% of patients who re-achieved inactive disease in P3 did so within 5 weeks (95% CI: 4-8 weeks, KM analysis). The observed trend of clinical improvement (P1), worsening (P2), and improvement (P3) was reflected in other clinical measures (Figure) plus measures of joint damage (Spondyloarthritis Research Consortium of Canada Sacroiliac Joint magnetic resonance imaging score) and quality of life (EQ-5D visual analog scale score); mean (standard deviation) score changes from each study period baseline–end were –6.1 (11.7) [P1], +1.5 (4.4) [P2], –2.0 (8.8) [P3] and +27.7 (26.7) [P1], –26.4 (30.5) [P2], +32.1 (26.3) [P3], respectively. There were no unexpected safety signals.Conclusion:For patients with nr-axSpA who achieved inactive disease with ETN and then discontinued treatment, a quarter maintained treatment-free inactive disease for 40 weeks and 50% maintained an ASDAS ESR score of <2.1 for ≥16 weeks. Re-starting ETN allowed 62% of patients who flared to re-achieve inactive disease within 12 weeks.References:[1]Van den Bosch F, et al.Ann Rheum Dis2019;78:896-7Acknowledgments:Medical writing support was provided by Lorna Forse, PhD, of Engage Scientific Solutions and was funded by Pfizer.Disclosure of Interests:Filip van den Bosch Consultant of: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Speakers bureau: AbbVie, Celgene Corporation, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, James Cheng-Chung Wei Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis, UCB Pharma, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer, Daniela Graham Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Chuanbo Zang Shareholder of: Pfizer, Employee of: Pfizer, Edmund Arthur Shareholder of: Pfizer, Employee of: Pfizer, Cecilia Borlenghi Shareholder of: Pfizer, Employee of: Pfizer, Bonnie Vlahos Shareholder of: Pfizer, Employee of: Pfizer, Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB
Collapse
|
25
|
Dalmao-Fernandez A, Lund J, Hermida Gómez T, Vazquez Mosquera ME, Rego-Perez I, Blanco FJ, Fernandez-Moreno M. THU0011 ANALYSIS OF METABOLIC STATUS IN CYBRIDS REVEALED IMPAIRED METABOLIC FLEXIBILITY IN OA PROCESS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:There are several metabolic pathways involved in cell metabolism, including glycolysis, tricarboxylic acid (TCA) cycle and fatty acid (FA) oxidation. Metabolic flexibility has previously described as the ability to respond or adapt to changes in metabolic demand; assessed by the ability to switch from fat to carbohydrate oxidation. In the last years there is a growing interest to assess the influence of metabolic flexibility, as a mechanism to explain how lipids can accumulate in the tissue. During OA, it has been established a relationship between mitochondrial dysfunction and cellular damage due to impairments in mitochondrial function and metabolic flexibility. Several studies have suggested that fatty acids may play an important role in OA development and progression.Objectives:The aim of this work was to examine the differences in glucose and fatty acid metabolism, with special focus on metabolic flexibility, in cybrids from healthy (N) or OA donors.Methods:Cybrids were developed using 143B.TK-Rho-0 cell line (nuclear donor) and platelets (mitochondrial donors) from healthy (N) and OA donors. Glucose and FA metabolism were measured using D-[14C(U)]glucose and [1-14C]oleic acid respectively. Metabolic flexibility was evaluated by co-culturing with glucose and oleic acid acutely by using inhibitors against glucose and FA oxidation, 20µM UK5099 and 10µM etomoxir, respectively. Incorporation of FA into lipid droplet (LD) was evaluated by thin layer chromatography and LD were stained by LD540 and analyzed by confocal microscope and flow cytometry. Mitochondrial dynamics was measured by real-time PCR method. Percentage of mitochondrial Anion Superoxide (O2-) production was evaluated incubating cells with MitoSox® using Flow Cytometer. Appropriate statistical analyses were performed with GraphPad Prism v6.Results:There were no changes in basal glucose metabolism between cybrids. N cybrids had higher acid-soluble metabolites, reflecting incomplete FA β-oxidation than OA cybrids. Comparing glucose and FA metabolism showed that both types of cybrids preferred to oxidize glucose. Co-culturing with glucose and Oleic acid, increased total cellular uptake and oxidation of glucose in N compared to basal condition (Figure-1) and in this condition the OA cybrids showed an increase in mitochondrial O2-production. Inhibition of FA oxidation by etomoxir increased complete glucose oxidation of N cybrids but not in OA cybrids that had a preference to oxidize oleic acid compared to basal condition. Gene expression of mitofusin-2 (MFN2) was higher in N than OA cybrids under inhibiting conditions. Combine these data indicate that N cybrids are more metabolically flexible and have better adaptative response than OA. Cybrids presented different lipid distribution patterns. Lipid droplet (LD) formation increased in both groups incubated in presence of FA. Furthermore, N cybrids showed less LD formation than OA.Conclusion:The results indicated that cybrids from OA patients had reduced metabolic flexibility compared to N cybrids. These results enhance our understanding of the mitochondria metabolism in OA, suggesting a mitochondrial dysfunction and impairment of metabolic flexibility during the OA process.Disclosure of Interests:Andrea Dalmao-Fernandez: None declared, Jenny Lund: None declared, Tamara Hermida Gómez: None declared, Maria Eugenia Vazquez Mosquera: None declared, Ignacio Rego-Perez: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer, Mercedes Fernandez-Moreno: None declared
Collapse
|
26
|
Julià A, Gómez A, Fernández Nebro A, Blanco FJ, Erra A, Sánchez Fernandez S, Monfort J, Alperi-López M, González-Álvaro I, Garcia de Vicuna R, Sanmartí R, Diaz Torne C, Marras Fernandez Cid C, Tornero Molina J, Palau N, Lastra RM, Lladós J, Marsal S. THU0016 EPIGENOMIC ANALYSIS OF RA PATIENTS SHOWS DISTINCT BIOLOGICAL PROCESSES ASSOCIATED WITH ANTI-TNF RESPONSE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Blocking Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for approximately 60% of patients with rheumatoid arthritis (RA). To date, however, the biological basis of the lack of efficacy of anti-TNF agents is unknown.Objectives:The objective of present study was to characterize the biological basis of anti-TNF lack of efficacy in RA using an epigenomic data approach in two steps: first, to assess the differential methylation changes between responders and non-responders and second, to use this differential methylation profile in a systems biology approach to infer differential methylated biological modules according to anti-TNF response.Methods:A total of n=68 patients diagnosed with RA according to the ACR-EULAR criteria belonging to 16 Hospitals across Spain were recruited. All patients were >18 years old, with more than 6 months of disease evolution and a baseline disease activity of DAS28 > 3.2. Treatment response was defined according to the EULAR criteria at week 12. Good and moderate responders were aggregated into a single responder group. Genomic DNA was collected at baseline and the methylation profile was assessed using the Illumina Infinium EPIC array, which interrogates 850,000 methylation CpG sites across the genome. Differential Methylation analysis, biological pathway association and the systems Biology approach using Protein-Protein Interaction Networks, were conducted using the R statistical language and the Bioconductor libraries.Results:From 68 anti-TNF treated patients, n=27 (39.7%) were good responders, n=26 (38.2%) moderate responders and n=15 (22.05%) non-responders at week 12 of treatment. Differential methylation analysis identified two distinctive biological profiles associated with the clinical response: responders were associated to interleukin and cytokine production, and non-responders were associated with biological pathways associated to TGF-Beta production and T cell regulation. Using these differentially methylated profiles, epigenetic modules with differentially methylated hotspots between responders and non-responders were also found. Two epigenetic modules with significant enrichment in inflammatory and interleukin production and immune regulatory processes were validated in an independent patient cohort.Conclusion:The epigenetic analysis of whole blood from RA patients using a module-based approach shows reproducible biological mechanisms associated with the response to anti-TNF therapy.Acknowledgments:We would like to thank the clinical researchers and patients participating in the IMID Consortium for their collaborationDisclosure of Interests:Antonio Julià: None declared, Antonio Gómez: None declared, Antonio Fernández Nebro: None declared, Francisco J. Blanco Grant/research support from: Sanofi-Aventis, Lilly, Bristol MS, Amgen, Pfizer, Abbvie, TRB Chemedica International, Glaxo SmithKline, Archigen Biotech Limited, Novartis, Nichi-iko pharmaceutical Co, Genentech, Jannsen Research & Development, UCB Biopharma, Centrexion Theurapeutics, Celgene, Roche, Regeneron Pharmaceuticals Inc, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, Ltd, Gilead Sciences Inc, Consultant of: Lilly, Bristol MS, Pfizer, Alba Erra: None declared, Simon Sánchez Fernandez: None declared, Jordi Monfort: None declared, Mercedes Alperi-López: None declared, Isidoro González-Álvaro Grant/research support from: Roche Laboratories, Consultant of: Lilly, Sanofi, Paid instructor for: Lilly, Speakers bureau: Abbvie, MSD, Roche, Lilly, Rosario Garcia de Vicuna Grant/research support from: BMS, Lilly, MSD, Novartis, Roche, Consultant of: Abbvie, Biogen, BMS, Celltrion, Gebro, Lilly, Mylan, Pfizer, Sandoz, Sanofi, Paid instructor for: Lilly, Speakers bureau: BMS, Lilly, Pfizer, Sandoz, Sanofi, Raimón Sanmartí Speakers bureau: Abbvie, Eli Lilly, BMS, Roche and Pfizer, Cesar Diaz Torne: None declared, Carlos Marras Fernandez Cid: None declared, Jesús Tornero Molina: None declared, Núria Palau: None declared, Raquel M Lastra: None declared, Jordi Lladós: None declared, Sara Marsal: None declared
Collapse
|
27
|
Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; 27:1578-1589. [PMID: 31278997 DOI: 10.1016/j.joca.2019.06.011] [Citation(s) in RCA: 1451] [Impact Index Per Article: 290.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Revised: 05/21/2019] [Accepted: 06/20/2019] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To update and expand upon prior Osteoarthritis Research Society International (OARSI) guidelines by developing patient-focused treatment recommendations for individuals with Knee, Hip, and Polyarticular osteoarthritis (OA) that are derived from expert consensus and based on objective review of high-quality meta-analytic data. METHODS We sought evidence for 60 unique interventions. A systematic search of all relevant databases was conducted from inception through July 2018. After abstract and full-text screening by two independent reviewers, eligible studies were matched to PICO questions. Data were extracted and meta-analyses were conducted using RevMan software. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Evidence Profiles were compiled using the GRADEpro web application. Voting for Core Treatments took place first. Four subsequent voting sessions took place via anonymous online survey, during which Panel members were tasked with voting to produce recommendations for all joint locations and comorbidity classes. We designated non-Core treatments to Level 1A, 1B, 2, 3, 4A, 4B, or 5, based on the percentage of votes in favor, in addition to the strength of the recommendation. RESULTS Core Treatments for Knee OA included arthritis education and structured land-based exercise programs with or without dietary weight management. Core Treatments for Hip and Polyarticular OA included arthritis education and structured land-based exercise programs. Topical non-steroidal anti-inflammatory drugs (NSAIDs) were strongly recommended for individuals with Knee OA (Level 1A). For individuals with gastrointestinal comorbidities, COX-2 inhibitors were Level 1B and NSAIDs with proton pump inhibitors Level 2. For individuals with cardiovascular comorbidities or frailty, use of any oral NSAID was not recommended. Intra-articular (IA) corticosteroids, IA hyaluronic acid, and aquatic exercise were Level 1B/Level 2 treatments for Knee OA, dependent upon comorbidity status, but were not recommended for individuals with Hip or Polyarticular OA. The use of Acetaminophen/Paracetamol (APAP) was conditionally not recommended (Level 4A and 4B), and the use of oral and transdermal opioids was strongly not recommended (Level 5). A treatment algorithm was constructed in order to guide clinical decision-making for a variety of patient profiles, using recommended treatments as input for each decision node. CONCLUSION These guidelines offer comprehensive and patient-centered treatment profiles for individuals with Knee, Hip, and Polyarticular OA. The treatment algorithm will facilitate individualized treatment decisions regarding the management of OA.
Collapse
Affiliation(s)
- R R Bannuru
- Center for Treatment Comparison and Integrative Analysis (CTCIA), Division of Rheumatology, Tufts Medical Center, Boston, MA, USA.
| | - M C Osani
- Center for Treatment Comparison and Integrative Analysis (CTCIA), Division of Rheumatology, Tufts Medical Center, Boston, MA, USA
| | - E E Vaysbrot
- Center for Treatment Comparison and Integrative Analysis (CTCIA), Division of Rheumatology, Tufts Medical Center, Boston, MA, USA
| | - N K Arden
- Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Oxford, Nottingham, UK; MRC Lifecourse Epidemiological Unit, University of Southampton, Southampton, UK
| | - K Bennell
- Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, University of Melbourne, Carlton, Victoria, Australia
| | - S M A Bierma-Zeinstra
- Department of General Practice, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the Netherlands; Department of Orthopedics, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the Netherlands
| | - V B Kraus
- Duke Molecular Physiology Institute and Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA
| | - L S Lohmander
- Dept. of Clinical Sciences, Orthopedics, Lund University, Lund, Sweden
| | - J H Abbott
- Centre for Musculoskeletal Outcomes Research (CMOR), Dept. of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
| | - M Bhandari
- Dept. of Orthopedic Surgery, McMaster University, Ontario, Canada
| | - F J Blanco
- Grupo de Investigación de Reumatología, INIBIC-Hospital Universitario, A Coruña, La Coruña, Spain; CICA-INIBIC Universidad de A Coruña, A Coruña, La Coruña, Spain
| | - R Espinosa
- National Institute of Rehabilitation, México City, Mexico; National Autonomous University of México, México City, Mexico
| | - I K Haugen
- Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
| | - J Lin
- Arthritis Clinic and Research Center, Peking University People's Hospital, Peking University, Beijing, China
| | - L A Mandl
- Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA
| | - E Moilanen
- The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland
| | - N Nakamura
- Institute for Medical Science in Sports, Osaka Health Science University, Osaka, Japan
| | - L Snyder-Mackler
- Dept. of Physical Therapy, STAR University of Delaware, Newark, DE, USA
| | - T Trojian
- Division of Sports Medicine, Drexel Sports Medicine, Philadelphia, PA, USA
| | - M Underwood
- Warwick Clinical Trials Unit, Warwick Medical School, Coventry, UK; University Hospitals of Coventry and Warwickshire, Coventry, UK
| | - T E McAlindon
- Center for Treatment Comparison and Integrative Analysis (CTCIA), Division of Rheumatology, Tufts Medical Center, Boston, MA, USA
| |
Collapse
|
28
|
Espona-Noguera A, Etxebarria-Elezgarai J, Saenz Del Burgo L, Cañibano-Hernández A, Gurruchaga H, Blanco FJ, Orive G, Hernández RM, Benito-Lopez F, Ciriza J, Basabe-Desmonts L, Pedraz JL. Type 1 Diabetes Mellitus reversal via implantation of magnetically purified microencapsulated pseudoislets. Int J Pharm 2019; 560:65-77. [PMID: 30742984 DOI: 10.1016/j.ijpharm.2019.01.058] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 01/24/2019] [Accepted: 01/25/2019] [Indexed: 01/13/2023]
Abstract
Microencapsulation of pancreatic islets for the treatment of Type I Diabetes Mellitus (T1DM) generates a high quantity of empty microcapsules, resulting in high therapeutic graft volumes that can enhance the host's immune response. We report a 3D printed microfluidic magnetic sorting device for microcapsules purification with the objective to reduce the number of empty microcapsules prior transplantation. In this study, INS1E pseudoislets were microencapsulated within alginate (A) and alginate-poly-L-lysine-alginate (APA) microcapsules and purified through the microfluidic device. APA microcapsules demonstrated higher mechanical integrity and stability than A microcapsules, showing better pseudoislets viability and biological function. Importantly, we obtained a reduction of the graft volume of 77.5% for A microcapsules and 78.6% for APA microcapsules. After subcutaneous implantation of induced diabetic Wistar rats with magnetically purified APA microencapsulated pseudoislets, blood glucose levels were restored into normoglycemia (<200 mg/dL) for almost 17 weeks. In conclusion, our described microfluidic magnetic sorting device represents a great alternative approach for the graft volume reduction of microencapsulated pseudoislets and its application in T1DM disease.
Collapse
Affiliation(s)
- A Espona-Noguera
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - J Etxebarria-Elezgarai
- BIOMICs-microfluidics Research Group, Microfluidics Cluster UPV/EHU, University of the Basque Country, Spain
| | - L Saenz Del Burgo
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - A Cañibano-Hernández
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - H Gurruchaga
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - F J Blanco
- INIBIC-Hospital Universitario La Coruña, La Coruña, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), La Coruña, Spain
| | - G Orive
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), BTI Biotechnology Institute, Vitoria-Gasteiz, Spain
| | - Rosa M Hernández
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - F Benito-Lopez
- AMMa LOAC Research Group, Microfluidics Cluster UPV/EHU, University of the Basque Country, Spain
| | - J Ciriza
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - L Basabe-Desmonts
- BIOMICs-microfluidics Research Group, Microfluidics Cluster UPV/EHU, University of the Basque Country, Spain; Basque Foundation of Science, IKERBASQUE, Spain.
| | - J L Pedraz
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
| |
Collapse
|
29
|
Rego-Pérez I, Blanco FJ, Roemer FW, Guermazi A, Ran D, Ashbeck EL, Fernández-Moreno M, Oreiro N, Hannon MJ, Hunter DJ, Kwoh CK. Mitochondrial DNA haplogroups associated with MRI-detected structural damage in early knee osteoarthritis. Osteoarthritis Cartilage 2018; 26:1562-1569. [PMID: 30036585 DOI: 10.1016/j.joca.2018.06.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 06/11/2018] [Accepted: 06/26/2018] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Magnetic resonance imaging (MRI)-detected structural features are associated with increased risk of radiographic osteoarthritis (ROA). Specific mitochondrial DNA (mtDNA) haplogroups have been associated with incident ROA. Our objective was to compare the presence of MRI-detected structural features across mtDNA haplogroups among knees that developed incident ROA. DESIGN Knees from the Osteoarthritis Initiative (OAI) that developed incident ROA during 48 months follow-up were identified from Caucasian participants. mtDNA haplogroups were assigned based on a single base extension assay. MRIs were obtained annually between baseline and 4-year follow-up and scored using the MRI Osteoarthritis Knee Score (MOAKS). The association between mtDNA haplogroups and MRI-detected structural features was estimated using log-binomial regression. Participants who carried haplogroup H served as the reference group. RESULTS The sample included 255 participants contributing 277 knees that developed ROA. Haplogroups included H (116, 45%), J (17, 7%), T (26, 10%), Uk (61, 24%), and the remaining less common haplogroups ("others") (35, 14%). Knees of participants with haplogroup J had significantly lower risk of medium/large bone marrow lesions (BMLs) in the medial compartment [3.2%, relative risks (RR) = 0.17; 95%CI: 0.05, 0.64; P = 0.009] compared to knees of participants who carried haplogroup H [16.3%], as did knees from participants within the "others" group [2.8%, RR = 0.20; 95%CI: 0.08, 0.55; P = 0.002], over the 4 year follow-up period. CONCLUSIONS mtDNA haplogroup J was associated with lower risk of BMLs in the medial compartment among knees that developed ROA. Our results offer a potential hypothesis to explain the mechanism underlying the previously reported protective association between haplogroup J and ROA.
Collapse
Affiliation(s)
- I Rego-Pérez
- Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, 15006. A Coruña, Spain
| | - F J Blanco
- Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, 15006. A Coruña, Spain
| | - F W Roemer
- Boston University School of Medicine, Boston, MA, USA; Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - A Guermazi
- Boston University School of Medicine, Boston, MA, USA
| | - D Ran
- The University of Arizona Arthritis Center, Tucson, AZ, USA; Department of Epidemiology and Biostatistics, University of Arizona, USA
| | - E L Ashbeck
- The University of Arizona Arthritis Center, Tucson, AZ, USA
| | - M Fernández-Moreno
- Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, 15006. A Coruña, Spain; Centro de investigación biomédica en Red, Bioingenieria, Biomatereial y Nanomedicina (CIBER-BBN), Spain
| | - N Oreiro
- Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, 15006. A Coruña, Spain
| | - M J Hannon
- Univ. of Pittsburgh Sch. of Med., Pittsburgh, PA, USA
| | - D J Hunter
- Department of Rheumatology, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia
| | - C K Kwoh
- The University of Arizona Arthritis Center, Tucson, AZ, USA; Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, USA.
| |
Collapse
|
30
|
Vela-Anero Á, Hermida-Gómez T, Gato-Calvo L, Vaamonde-García C, Díaz-Prado S, Meijide-Faílde R, Blanco FJ, Burguera EF. Long-term effects of hydrogen sulfide on the anabolic-catabolic balance of articular cartilage in vitro. Nitric Oxide 2017; 70:42-50. [PMID: 28821460 DOI: 10.1016/j.niox.2017.08.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 08/10/2017] [Accepted: 08/12/2017] [Indexed: 12/25/2022]
Abstract
Healthy cartilage maintenance relies on an equilibrium among the anabolic and catabolic processes in chondrocytes. With the onset of osteoarthritis (OA), increased interleukin (IL)-1β levels induce an inhibition of the synthesis of extracellular matrix (ECM) proteins, as well as an increase in proteases. This eventually leads to a predominance of the catabolic phenotype and the progressive loss of articular cartilage. Hydrogen sulfide (H2S) is a small gaseous molecule recognized as the third endogenous gasotransmitter. When administered exogenously, it has shown anti-inflammatory and anti-catabolic properties in several in vitro and in vivo models. Here, OA cartilage disks were co-cultured in vitro with IL-1β (5 ng/ml) and NaSH or GYY4137 (200 or 1000 μM) for 21 days. The ability of these two H2S-producing compounds to avoid long term extracellular matrix (ECM) destruction was evaluated. We used a glycosaminoglycan (GAG) quantification kit histology and immunohistochemistry (IHC) to evaluate matrix proteins degradation and matrix metalloproteinases (MMP) abundance. Through the GAGs quantification assay, safranin O (S-O) and toluidine blue (TB) stains, and keratan/chondroitin sulfate (KS/ChS) IHCs it was shown that co-stimulation with H2S-forming reagents effectively avoided GAGs destruction. Both Masson's trichrome (MT) stain and collagen (col) type II IHC, as well as aggrecan (agg) IHC demonstrated that not only were these proteins protected but even promoted, their abundance being higher than in the basal condition. Further, stains also demonstrated that positivity in the inter-territorial and intra-cellular for the different matrix components were rescued, suggesting that NaSH and GYY4137 might also have pro-anabolic effects. In addition, a clear protective effect against the increased MMPs levels was seen, since increased MMP3 and 13 levels were subsequently reduced with the co-stimulation with sulfide compounds. In general, GYY4137 was more effective than NaSH, and increasing the dose improved the results. This study demonstrates that H2S anti-catabolic effects, which had been previously proven in short-term (24-48 h) in vitro cellular models, are maintained over time directly in OA cartilage tissue.
Collapse
Affiliation(s)
- Á Vela-Anero
- Grupo de Terapia Celular y Medicina Regenerativa, Departamento de Ciencias Biomédicas, Medicina y Fisioterapia, Facultad de Ciencias de la Salud, Universidade da Coruña, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Grupo de Bioingieneria Tisular y Terapia Celular (GBTTC), Spain.
| | - T Hermida-Gómez
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Grupo de Bioingieneria Tisular y Terapia Celular (GBTTC), Spain; Grupo de Investigación en Reumatología, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain.
| | - L Gato-Calvo
- Grupo de Investigación en Reumatología, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain.
| | - C Vaamonde-García
- Grupo de Terapia Celular y Medicina Regenerativa, Departamento de Ciencias Biomédicas, Medicina y Fisioterapia, Facultad de Ciencias de la Salud, Universidade da Coruña, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain.
| | - S Díaz-Prado
- Grupo de Terapia Celular y Medicina Regenerativa, Departamento de Ciencias Biomédicas, Medicina y Fisioterapia, Facultad de Ciencias de la Salud, Universidade da Coruña, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Grupo de Bioingieneria Tisular y Terapia Celular (GBTTC), Spain.
| | - R Meijide-Faílde
- Grupo de Terapia Celular y Medicina Regenerativa, Departamento de Ciencias Biomédicas, Medicina y Fisioterapia, Facultad de Ciencias de la Salud, Universidade da Coruña, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain.
| | - F J Blanco
- Grupo de Investigación en Reumatología, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain.
| | - E F Burguera
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Grupo de Bioingieneria Tisular y Terapia Celular (GBTTC), Spain; Grupo de Investigación en Reumatología, Instituto de Investigación Biomédica de A Coruña-Complejo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde, A Coruña, Spain.
| |
Collapse
|
31
|
Ribeiro M, López de Figueroa P, Nogueira-Recalde U, Centeno A, Mendes AF, Blanco FJ, Caramés B. Diabetes-accelerated experimental osteoarthritis is prevented by autophagy activation. Osteoarthritis Cartilage 2016; 24:2116-2125. [PMID: 27390029 DOI: 10.1016/j.joca.2016.06.019] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 06/17/2016] [Accepted: 06/27/2016] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Type 2 Diabetes (T2D) is a risk factor for osteoarthritis (OA). Autophagy, an essential homeostasis mechanism in articular cartilage, is defective in T2D and OA. However, how T2D may influence OA progression is still unknown. We aimed to determine how diabetes affects cartilage integrity and whether pharmacological activation of autophagy has efficacy in diabetic mice (db/db mice) with OA. DESIGN Experimental OA was performed in the right knee of 9 weeks-old C57Bl/6J male mice (Lean group, N = 8) and of 9 weeks-old B6.BKS (D)-Leprdb male mice (db/db group, N = 16) by transection of medial meniscotibial and medial collateral ligaments. Left knee was employed as control knee. Rapamycin (2 mg/kg weight/day) or Vehicle (dimethyl sulfoxide) were administered intraperitoneally three times a week for 10 weeks. Histopathology of articular cartilage and synovium was evaluated by using semiquantitative scoring and synovitis grading systems, respectively. Immunohistochemistry was employed to evaluate the effect of diabetes and Rapamycin on cartilage integrity and OA biomarkers. RESULTS Cartilage damage was increased in db/db mice compared to Lean mice after experimental OA, while no differences are observed in the control knee. Cartilage damage and synovium inflammation were reduced by Rapamycin treatment of OA-db/db mice. This protection was accompanied with a decrease in MMP-13 expression and decreased interleukin 12 (IL-12) levels. Furthermore, autophagy was increased and cartilage cellularity was maintained, suggesting that mammalian target of rapamycin (mTOR) targeting prevents joint physical harm. CONCLUSION Our findings indicate that diabetic mice exhibit increased joint damage after experimental OA, and that autophagy activation might be an effective therapy for diabetes-accelerated OA.
Collapse
Affiliation(s)
- M Ribeiro
- Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain; Centre for Neuroscience and Cell Biology and Faculty of Pharmacy, University of Coimbra, Portugal
| | - P López de Figueroa
- Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain
| | - U Nogueira-Recalde
- Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain
| | - A Centeno
- Unidad de Cirugía Experimental, Centro Tecnológico de Formación, INIBIC-CHUAC, Spain
| | - A F Mendes
- Centre for Neuroscience and Cell Biology and Faculty of Pharmacy, University of Coimbra, Portugal
| | - F J Blanco
- Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain
| | - B Caramés
- Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain.
| |
Collapse
|
32
|
Garcia-Martinez V, Lopez Sanchez C, Hamed W, Hamed W, Hsu JH, Ferrer-Lorente R, Alshamrani M, Pizzicannella J, Vindis C, Badi I, Korte L, Voellenkle C, Niculescu LS, Massaro M, Babaeva AR, Da Silva F, Woudstra L, Berezin A, Bae MK, Del Giudice C, Bageghni SA, Krobert K, Levay M, Vignier N, Ranieri A, Magenta A, Orlandi A, Porro B, Jeon ES, Omori Y, Herold J, Barnett GA, Grochot-Przeczek A, Korpisalo P, Deffge C, Margariti A, Rong W, Maring JA, Gambardella J, Mitrofan CG, Karpinska O, Morbidelli L, Wilkinson FL, Berezin A, Kostina AS, De Mey JGR, Kumar A, Lupieri A, Pellet-Many C, Stamatiou R, Gromotowicz A, Dickhout A, Murina M, Roka-Moiia YM, Malinova L, Diaz-Canestro C, Vigliarolo T, Cuzzocrea S, Szantai A, Medic B, Cassambai S, Korda A, Revnic CR, Borile G, Diokmetzidou A, Murfitt L, Budko A, Fiordelisi A, De Wijs-Meijler DPM, Gevaert AB, Noriega De La Colina A, Benes J, Guillermo Solache Berrocal GSB, Gafarov V, Zhebel VM, Prakaschandra R, Stepien EL, Smith LE, Carluccio MA, Timasheva Y, Paci M, Dorofeyeva NA, Chimed CH, Petelina TI, Sorop O, Genis A, Parepa IR, Tscharre M, Krestjyaninov MV, Maia-Rocha C, Borges L, Sasonko ML, Kapel SS, Stam K, Sommariva E, Stojkovic S, O'reilly J, Chiva-Blanch G, Malinova L, Evtushenko A, Skopal J, Sunderland N, Gegenava T, Charnaia MA, Di Lascio N, Tarvainen SJ, Malandraki-Miller S, Uitterdijk A, Benzoni P, Ruivo E, Humphrey EJ, Arokiaraj MC, Franco D, Garcia-Lopez V, Aranega A, Lopez-Sanchez C, Franco D, Garcia-Lopez V, Aranega A, Garcia-Martinez V, Tayel S, Khader H, El-Helbawy N, Tayel S, Alrefai A, El-Barbary H, Wu JR, Dai ZK, Yeh JL, Sanjurjo-Rodriguez C, Richaud-Patin Y, Blanco FJ, Badimon L, Raya A, Cahill PA, Diomede F, Merciaro I, Trubiani O, Nahapetyan H, Swiader A, Faccini J, Boya P, Elbaz M, Zeni F, Burba I, Bertolotti M, Capogrossi MC, Pompilio G, Raucci A, Widmer-Teske R, Dutzmann J, Bauersachs J, Donde K, Daniel JM, Sedding DG, Simionescu N, Sanda GM, Carnuta MG, Stancu CS, Popescu AC, Popescu MR, Vlad A, Dimulescu DR, Sima AV, Scoditti E, Pellegrino M, Calabriso N, Carluccio MA, Storelli C, De Caterina R, Solodenkova KS, Kalinina EV, Usachiova MN, Lappalainen J, Lee-Rueckert MDEC, Kovanen PT, Biesbroek PS, Emmens RWE, Van Rossum AC, Juffermans LJM, Niessen JWM, Krijnen PAJ, Kremzer A, Samura T, Berezina T, Gronenko E, Kim MK, Park HJ, Bae SK, Sorriento D, Ciccarelli M, Vernieri E, Campiglia P, Trimarco B, Iaccarino G, Hemmings KE, Porter KE, Ainscough JF, Drinkhill MJ, Turner NA, Hiis HG, Cosson MV, Levy FO, Wieland T, Macquart C, Chatzifrangkeskou M, Evans A, Bonne G, Muchir A, Kemp E, Avkiran M, Carlomosti F, D'agostino M, Beji S, Zaccagnini G, Maimone B, Di Stefano V, De Santa F, Cordisco S, Antonini A, Ciarapica R, Dellambra E, Martelli F, Avitabile D, Capogrossi MC, Scioli MG, Bielli A, Agostinelli S, Tarquini C, Tarallo V, De Falco S, Zaninoni A, Fiorelli S, Bianchi P, Teruzzi G, Squellerio I, Turnu L, Lualdi A, Tremoli E, Cavalca V, Lee YJ, Ju ES, Choi JO, Lee GY, Lim BK, Manickam MANOJ, Jung SH, Omiya S, Otsu K, Deffge C, Nowak S, Wagner M, Braun-Dullaeus RC, Kostin S, Daniel JM, Francke A, Subramaniam S, Kanse SM, Al-Lamee K, Schofield CJ, Egginton S, Gershlick AH, Kloska D, Kopacz A, Augustyniak A, Dulak J, Jozkowicz A, Hytonen J, Halonen P, Taavitsainen J, Tarvainen S, Hiltunen T, Liimatainen T, Kalliokoski K, Knuuti J, Yla-Herttuala S, Wagner M, Weinert S, Isermann B, Lee J, Braun-Dullaeus RC, Herold J, Cochrane A, Kelaini S, Bojdo J, Vila Gonzalez M, Hu Y, Grieve D, Stitt AW, Zeng L, Xu Q, Margariti A, Reglin B, Xiang W, Nitzsche B, Maibier M, Pries AR, Vrijsen KR, Chamuleau SAJ, Verhage V, Metz CHG, Lodder K, Van Eeuwijk ECM, Van Dommelen SM, Doevendans PA, Smits AM, Goumans MJ, Sluijter JPG, Sorriento D, Bova M, Loffredo S, Trimarco B, Iaccarino G, Ciccarelli M, Appleby S, Morrell N, Baranowska-Kuczko M, Kloza M, Ambrozewicz E, Kozlowski M, Malinowska B, Kozlowska H, Monti M, Terzuoli E, Ziche M, Mahmoud AM, Jones AM, Wilkinson JA, Romero M, Duarte J, Alexander MY, Kremzer A, Berezina T, Gronenko E, Faggian G, Kostareva AA, Malashicheva AB, Leurgans TM, Nguyen TN, Irmukhamedov A, Riber LP, Mcgeogh R, Comer S, Blanco Fernandez A, Ghigo A, Blaise R, Smirnova NF, Malet N, Vincent P, Limon I, Gayral S, Hirsch E, Laffargue M, Mehta V, Zachary I, Aidonidis I, Kramkowski K, Miltyk W, Kolodziejczyk P, Gradzka A, Szemraj J, Chabielska E, Dijkgraaf I, Bitsch N, Van Hoof S, Verhaegen F, Koenen R, Hackeng TM, Roshchupkin DI, Buravleva KV, Sergienko VI, Zhernossekov DD, Rybachuk VM, Grinenko TV, Furman N, Dolotovskaya P, Shamyunov M, Denisova T, Reiner M, Akhmedov A, Keller S, Miranda M, Briand S, Barile L, Kullak-Ublick G, Luscher T, Camici G, Guida L, Magnone M, Ameri P, Lazzarini E, Fresia C, Bruzzone S, Zocchi E, Di Paola R, Cordaro M, Crupi R, Siracusa R, Campolo M, Bruschetta G, Fusco R, Pugliatti P, Esposito E, Paloczi J, Ruivo E, Gaspar R, Dinnyes A, Kobolak J, Ferdinandy P, Gorbe A, Todorovic Z, Krstic D, Savic Vujovic K, Jovicic D, Basta Jovanovic G, Radojevic Skodric S, Prostran M, Dean S, Mee CJ, Harvey KL, Hussain A, Pena C, Paltineanu B, Voinea S, Revnic F, Ginghina C, Zaglia T, Ceriotti P, Campo A, Carullo P, Armani A, Coppini R, Vida V, Olivotto I, Stellin G, Rizzuto R, De Stefani D, Sandri M, Catalucci D, Mongillo M, Soumaka E, Kloukina I, Tsikitis M, Makridakis M, Varela A, Davos C, Vlachou A, Capetanaki Y, Iqbal MM, Bennett H, Davenport B, Pinali C, Cooper G, Cartwright E, Kitmitto A, Strutynska NA, Mys LA, Sagach VF, Franco A, Sorriento D, Trimarco B, Iaccarino G, Ciccarelli M, Verzijl A, Stam K, Van Duin R, Reiss IKM, Duncker DJ, Merkus D, Shakeri H, Orije M, Leloup AJ, Van Hove CE, Van Craenenbroeck EM, De Meyer GRY, Vrints CJ, Lemmens K, Desjardins-Creapeau L, Wu R, Lamarre-Cliche M, Larochelle P, Bherer L, Girouard H, Melenovsky M, Kvasilova A, Benes J, Ruskova K, Sedmera D, Ana Barral ABV, Martin Fernandez M, Pablo Roman Garcia PRG, Juan Carlos Llosa JCLL, Manuel Naves Diaz MND, Cesar Moris CM, Jorge B Cannata-Andia JBCA, Isabel Rodriguez IR, Voevoda M, Gromova E, Maximov V, Panov D, Gagulin I, Gafarova A, Palahniuk H, Pashkova IP, Zhebel NV, Starzhynska OL, Naidoo DP, Rawojc K, Enguita FJ, Grudzien G, Cordwell SJ, White MY, Massaro M, Scoditti E, Calabriso N, Pellegrino M, Martinelli R, Gatta V, De Caterina R, Nasibullin TR, Erdman VV, Tuktarova IA, Mustafina OE, Hyttinen J, Severi S, Vorobyov GG, Sagach VF, Batmyagmar KH, Lkhagvasuren Z, Gapon LI, Musikhina NA, Avdeeva KS, Dyachkov SM, Heinonen I, Van Kranenburg M, De Beer VJ, Octavia Y, Van Geuns RJ, Van Den Meiracker AH, Van Der Velden J, Merkus D, Duncker DJ, Everson FP, Ogundipe T, Grandjean T, De Boever P, Goswami N, Strijdom H, Suceveanu AI, Suceveanu AP, Mazilu L, Tofoleanu DE, Catrinoiu D, Rohla M, Hauser C, Huber K, Wojta H, Weiss TW, Melnikova MA, Olezov NV, Gimaev RH, Khalaf H, Ruzov VI, Adao R, Mendes-Ferreira P, Santos-Ribeiro D, Rademaker M, Leite-Moreira AF, Bras-Silva C, Alvarenga LAA, Falcao RSP, Dias RR, Lacchini S, Gutierrez PS, Michel JB, Gurfinkel YUI, Atkov OYU, Teichert M, Korn C, Mogler C, Hertel S, Arnold C, Korff T, Augustin HG, Van Duin RWB, De Wijs-Meijler DPM, Verzijl A, Duncker DJ, Merkus D, D'alessandra Y, Farina FM, Casella M, Catto V, Carbucicchio C, Dello Russso A, Stadiotti I, Brambilla S, Chiesa M, Giacca M, Colombo GI, Pompilio G, Tondo C, Ahlin F, Andric T, Tihanyi D, Wojta J, Huber K, O'connell E, Butt A, Murphy L, Pennington S, Ledwidge M, Mcdonald K, Baugh J, Watson C, Suades R, Crespo J, Estruch R, Badimon L, Dyachenko A, Ryabukho V, Evtushenko V, Saushkina YU, Lishmanov YU, Smyshlyaev K, Bykov A, Popov S, Pavlyukova E, Anfinogenova Y, Szigetfu E, Kapornai B, Forizs E, Jenei ZS, Nagy Z, Merkely B, Zima E, Cai A, Dworakowski R, Gibbs T, Piper S, Jegard N, Mcdonagh T, Gegenava M, Dementieva II, Morozov YUA, Barsanti C, Stea F, Lenzarini F, Kusmic C, Faita F, Halonen PJ, Puhakka PH, Hytonen JP, Taavitsainen JM, Yla-Herttuala S, Supit EA, Carr CA, Groenendijk BCW, Gorsse-Bakker C, Panasewicz A, Sneep S, Tempel D, Van Der Giessen WJ, Duncker DJ, Rys J, Daraio C, Dell'era P, Paloczi J, Pigler J, Eder A, Ferdinandy P, Eschenhagen T, Gorbe A, Mazo MM, Amdursky N, Peters NS, Stevens MM, Terracciano CM. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Association of deletion allele of insertion/deletion polymorphism in alpha 2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus295Association of G1359A polymorphism of the endocannabinoid type 1 receptor (CNR1) with coronary artery disease (CAD) with type 2 diabetes mellitusCell growth, differentiation and stem cells - Vascular298Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells: a role of Notch signaling in postnatal closure of ductus arteriosus299Mesenchymal stromal-like cells (MLCs) derived from induced pluripotent stem (iPS) cells: a promising therapeutic option to promote neovascularization300Sonic Hedgehog promotes mesenchymal stem cell differentiation to vascular smooth muscle cells in cardiovacsular disease301Proinflammatory cytokine secretion and epigenetic modification in endothelial cells treated LPS-GinfivalisCell death and apoptosis - Vascular304Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipidsTranscriptional control and RNA species - Vascular307MicroRNA-34a role in vascular calcification308Local delivery of a miR-146a inhibitor utilizing a clinically applicable approach attenuates neointima formation after vascular injury309Long noncoding RNA landscape of hypoxic endothelial cells310Specific circulating microRNAs levels associate with hypertension, hyperglycemia and dysfunctional HDL in acute coronary syndrome patientsCytokines and cellular inflammation - Vascular313Phosphodiesterase5A up-regulation in vascular endothelium under pro-inflammatory conditions: a newly disclosed anti-inflammatory activity for the omega-3polyunsaturated aatty acid docosahexaenoic acid314Cardiovascular risk modifying with extra-low dose anticytokine drugs in rhematoid arthritis315Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation316Lymphocytic myocarditis coincides with increased plaque inflammation and plaque hemorrhage in coronary arteries, facilitating myocardial infarction317Serum osteoprotegerin level predictsdeclined numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndromeGrowth factors and neurohormones - Vascular320Effect of gastrin-releasing peptide (GRP) on vascular inflammationSignal transduction - Heart323A new synthetic peptide regulates hypertrophy in vitro through means of the inhibition of nfkb324Inducible fibroblast-specific knockout of p38 alpha map kinase is cardioprotective in a mouse model of isoproterenol-induced cardiac hypertrophy325Regulation of beta-adrenoceptor-evoked inotropic responses by inhibitory G protein, adenylyl cyclase isoforms 5 and 6 and phosphodiesterases326Binding to RGS3 and stimulation of M2 muscarinic acetylcholine receptors modulates the substrate specificity of p190RhoGAP in cardiac myocytes327Cardiac regulation of post-translational modifications, parylation and deacetylation in LMNA dilated cardiomyopathy mouse model328Beta-adrenergic regulation of the b56delta/pp2a holoenzyme in cardiac myocytes through b56delta phosphorylation at serine 573Nitric oxide and reactive oxygen species - Vascular331Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1 and eNOS332Antioxidant therapy prevents oxidative stress-induced endothelial dysfunction and Enhances Wound Healing333Morphological and biochemical characterization of red blood cell in coronary artery diseaseCytoskeleton and mechanotransduction - Heart336Novel myosin activator, JSH compounds, increased myocardial contractility without chronotropic effect in ratsExtracellular matrix and fibrosis - Vascular339Ablation of Toll-like receptor 9 causes cardiac rupture after myocardial infarction by attenuating proliferation and differentiation of cardiac fibroblasts340Altered vascular remodeling in the mouse hind limb ischemia model in Factor VII activating protease (FSAP) deficiencyVasculogenesis, angiogenesis and arteriogenesis343Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion344Nrf2 drives angiogenesis in transcription-independent manner: new function of the master regulator of oxidative stress response345Angiogenic gene therapy, despite efficient vascular growth, is not able to improve muscle function in normoxic or chronically ischemic rabbit hindlimbs -role of capillary arterialization and shunting346Effect of PAR-1 inhibition on collateral vessel growth in the murine hind limb model347Quaking is a key regulator of endothelial cell differentiation, neovascularization and angiogenesis348"Emerging angiogenesis" in the chick chorioallantoic membrane (CAM). An in vivo study349Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis in vitro and in vivo via EMMPRINEndothelium352Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate Ca2+ intracellular level in endothelial cells353The roles of bone morphogenetic proteins 9 and 10 in endothelial inflammation and atherosclerosis354The contribution of GPR55 to the L-alpha-lysophosphatidylinositol-induced vasorelaxation in isolated human pulmonary arteries355The endothelial protective ACE inhibitor Zofenoprilat exerts anti-inflammatory activities through H2S production356A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction357Endothelial progenitor cells to apoptotic endothelial cell-derived microparticles ration differentiatesas preserved from reduced ejection fractionheart failure358Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic aneurysm359Endothelin ETB receptors mediate relaxing responses to insulin in pericardial resistance arteries from patients with cardiovascular disease (CVD)Smooth muscle and pericytes362CX3CR1 positive myeloid cells regulate vascular smooth muscle tone by inducing calcium oscillations via activation of IP3 receptors363A novel function of PI3Kg on cAMP regulation, role in arterial wall hyperplasia through modulation of smooth muscle cells proliferation364NRP1 and NRP2 play important roles in the development of neointimal hyperplasia in vivo365Azithromycin induces autophagy in aortic smooth muscle cellsCoagulation, thrombosis and platelets368The real time in vivo evaluation of platelet-dependent aldosterone prothrombotic action in mice369Development of a method for in vivo detection of active thrombi in mice370The antiplatelet effects of structural analogs of the taurine chloramine371The influence of heparin anticoagulant drugs on functional state of human platelets372Regulation of platelet aggregation and adenosine diphosphate release by d dimer in acute coronary syndrome (in vitro study)Oxygen sensing, ischaemia and reperfusion375Sirtuin 5 mediates brain injury in a mouse model of cerebral ischemia-reperfusion376Abscisic acid: a new player in cardiomyocyte protection from ischaemia?377Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo378Identification of stem cell-derived cardiomyocytes using cardiac specific markers and additional testing of these cells in simulated ischemia/reperfusion system379Single-dose intravenous metformin treatment could afford significant protection of the injured rat kidney in an experimental model of ischemia-reperfusion380Cardiotoxicity of long acting muscarinic receptor antagonists used for chronic obstructive pulmonary disease381Dependence antioxidant potential on the concentration of amino acids382The impact of ischemia-reperfusion on physiological parameters,apoptosis and ultrastructure of rabbit myocardium with experimental aterosclerosisMitochondria and energetics385MicroRNA-1 dependent regulation of mitochondrial calcium uniporter (MCU) in normal and hypertrophied hearts386Mitochondrial homeostasis and cardioprotection: common targets for desmin and aB-crystallin387Overexpression of mitofusin-2 (Mfn2) and associated mitochondrial dysfunction in the diabetic heart388NO-dependent prevention of permeability transition pore (MPTP) opening by H2S and its regulation of Ca2+ accumulation in rat heart mitochondria389G protein coupled receptor kinase 2 (GRK2) is fundamental in recovering mitochondrial morphology and function after exposure to ionizing radiation (IR)Gender issues392Sex differences in pulmonary vascular control; focus on the nitric oxide pathwayAging395Heart failure with preserved ejection fraction develops when feeding western diet to senescence-accelerated mice396Cardiovascular markers as predictors of cognitive decline in elderly hypertensive patients397Changes in connexin43 in old rats with volume overload chronic heart failureGenetics and epigenetics400Calcium content in the aortic valve is associated with 1G>2G matrix metalloproteinase 1 polymorphism401Neuropeptide receptor gene s (NPSR1) polymorphism and sleep disturbances402Endothelin-1 gene Lys198Asn polymorphism in men with essential hypertension complicated and uncomplicated with chronic heart failure403Association of common polymorphisms of the lipoprotein lipase and pon1 genes with the metabolic syndrome in a sample of community participantsGenomics, proteomics, metabolomics, lipidomics and glycomics405Gene expression quantification using multiplexed color-coded probe pairs to determine RNA content in sporadic cardiac myxoma406Large-scale phosphorylation study of the type 2 diabetic heart subjected to ischemia / reperfusion injury407Transcriptome-based identification of new anti-inflammatory properties of the olive oil hydroxytyrosol in vascular endothelial cell under basal and proinflammatory conditions408Gene polymorphisms combinations and risk of myocardial infarctionComputer modelling, bioinformatics and big data411Comparison of the repolarization reserve in three state-of-the-art models of the human ventricular action potentialMetabolism, diabetes mellitus and obesity414Endothelial monocyte-activating polypeptide-II improves heart function in type -I Diabetes mellitus415Admission glucose level is independent predictor of impaired left ventricular function in patients with acute myocardial infarction: a two dimensional speckle-tracking echocardiography study416Association between biochemical markers of lipid profile and inflammatory reaction and stiffness of the vascular wall in hypertensive patients with abdominal obesity417Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening418Investigating the cardiovascular effects of antiretroviral drugs in a lean and high fat/sucrose diet rat model of obesity419Statins in the treatment of non-alcoholic steatohepatitis (NASH). Our experience from a 2-year prospective study in Constanta County, Romania420Epicardial adipose tissue as a predictor of cardiovascular outcome in patients with ACS undergoing PCI?Arterial and pulmonary hypertension423Dependence between heart rhythm disorers and ID polymorphism of ACE gene in hypertensive patients424Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension425Inhibition of TGf-b axis and action of renin-angiotensin system in human ascending aorta aneurysms426Early signs of microcirculation and macrocirculation abnormalities in prehypertension427Vascular smooth muscle cell-expressed Tie-2 controls vascular tone428Cardiac and vascular remodelling in the development of chronic thrombo-embolic pulmonary hypertension in a novel swine modelBiomarkers431Arrhythmogenic cardiomyopathy: a new, non invasive biomarker432Can circulating microRNAs distinguish type 1 and type 2 myocardial infarction?433Design of a high-throughput multiplex proteomics assay to identify left ventricular diastolic dysfunction in diabetes434Monocyte-derived and P-selectin-carrying microparticles are differently modified by a low fat diet in patients with cardiovascular risk factors who will and who will not develop a cardiovascular event435Red blood cell distribution width assessment by polychromatic interference microscopy of thin films in chronic heart failure436Invasive and noninvasive evaluation of quality of radiofrequency-induced cardiac denervation in patients with atrial fibrillation437The effect of therapeutic hypothermia on the level of brain derived neurotrophic factor (BDNF) in sera following cardiopulmonary resustitation438Novel biomarkers to predict outcome in patients with heart failure and severe aortic stenosis439Biological factors linking depression and anxiety to cardiovascular disease440Troponins and myoglobin dynamic at coronary arteries graftingInvasive, non-invasive and molecular imaging443Diet composition effects on the genetic typing of the mouse ob mutation: a micro-ultrasound characterization of cardiac function, macro and micro circulation and liver steatosis444Characterization of pig coronary and rabbit aortic lesions using IV-OCT quantitative analysis: correlations with histologyGene therapy and cell therapy447Enhancing the survival and angiogenic potential of mouse atrial mesenchymal cells448VCAM-1 expression in experimental myocardial infarction and its relation to bone marrow-derived mononuclear cell retentionTissue engineering451Advanced multi layered scaffold that increases the maturity of stem cell-derived human cardiomyocytes452Response of engineered heart tissue to simulated ischemia/reperfusion in the presence of acute hyperglycemic conditions453Serum albumin hydrogels prevent de-differentiation of neonatal cardiomyocytes454A novel paintbrush technique for transfer of low viscosity ultraviolet light curable cyan methacrylate on saline immersed in-vitro sheep heart. Cardiovasc Res 2016. [DOI: 10.1093/cvr/cvw149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Ribeiro M, López de Figueroa P, Blanco FJ, Mendes AF, Caramés B. Insulin decreases autophagy and leads to cartilage degradation. Osteoarthritis Cartilage 2016; 24:731-9. [PMID: 26549531 DOI: 10.1016/j.joca.2015.10.017] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Revised: 10/16/2015] [Accepted: 10/28/2015] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Autophagy, a key homeostasis mechanism, is defective in Osteoarthritis (OA) and Type 2 Diabetes (T2D). T2D has been proposed as a risk factor for OA. We hypothesized that diabetes impairs articular cartilage integrity by decreasing autophagy. Our objective was to investigate the effects of high glucose and insulin, characteristics of T2D, on cartilage homeostasis. METHODS Immortalized human chondrocytes (TC28a2) and primary human chondrocytes (HC) were cultured in 25 mM or 0 mM glucose and treated with insulin (10, 100, 500 nM) for 2, 6 or 24 h. Activity of LC3-II, Akt and rpS6 was evaluated by Western blotting (WB). Human cartilage explants were cultivated with 25 mM glucose and insulin (100,1000 nM) for 24 h to evaluate histopathology. MMP-13 and IL-1β expression was determined by immunohistochemistry and WB. Effects of Rapamycin (10 μM) were analyzed by WB. LC3 and rpS6 expression was determined by WB in chondrocytes from Healthy, Non Diabetic-OA and Diabetic-OA patients. RESULTS Insulin downregulates autophagy by reducing LC3 II expression and increasing Akt and rpS6 phosphorylation. Loss of proteoglycans and increased MMP-13 and IL-1β expression was observed after insulin treatment. Autophagy activation by rapamycin reversed insulin effects. Importantly, chondrocytes from diabetic-OA patients showed decreased LC3 and increased p-rpS6 expression compared to Healthy and Non-Diabetic OA patients. CONCLUSIONS These results suggest that decreased autophagy might be a mechanism by which diabetes influences cartilage degradation. Pharmacological activation of autophagy may be an effective therapeutic approach to prevent T2D-induced cartilage damage.
Collapse
Affiliation(s)
- M Ribeiro
- Grupo de Biología del Cartílago, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain; Centre for Neuroscience and Cell Biology and Faculty of Pharmacy, University of Coimbra, Portugal
| | - P López de Figueroa
- Grupo de Biología del Cartílago, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain
| | - F J Blanco
- Grupo de Biología del Cartílago, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain
| | - A F Mendes
- Centre for Neuroscience and Cell Biology and Faculty of Pharmacy, University of Coimbra, Portugal
| | - B Caramés
- Grupo de Biología del Cartílago, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Spain.
| |
Collapse
|
34
|
Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage 2015; 23:1233-41. [PMID: 25865392 PMCID: PMC4516635 DOI: 10.1016/j.joca.2015.03.036] [Citation(s) in RCA: 346] [Impact Index Per Article: 38.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Revised: 03/18/2015] [Accepted: 03/31/2015] [Indexed: 02/02/2023]
Abstract
Osteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulate use of standardized nomenclature for OA that could serve as building blocks for describing OA and defining OA phenotypes, in short to provide unifying disease concepts for a heterogeneous disorder; and (2) To stimulate establishment of ROAD (Risk of OA Development) and ROAP (Risk of OA Progression) tools analogous to the FRAX™ instrument for predicting risk of fracture in osteoporosis; and (3) To stimulate formulation of tools for identifying disease in its early preradiographic and/or molecular stages - REDI (Reliable Early Disease Identification). Consensus around more sensitive and specific diagnostic criteria for OA could spur development of disease modifying therapies for this entity that has proved so recalcitrant to date. We fully acknowledge that as we move forward, we expect to develop more sophisticated definitions, terminology and tools.
Collapse
Affiliation(s)
- V B Kraus
- Duke Molecular Physiology Institute and Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
| | - F J Blanco
- Grupo de Proteomica, ProteoRed/ISCIII, Servicio de Reumatologia, Instituto de Investigación Biomedica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), As Xubias, 15006, A Coruña, Spain
| | - M Englund
- Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston University, MA, USA
| | | | - L S Lohmander
- Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden; Research Unit for Musculoskeletal Function and Physiotherapy, and Department of Orthopedics and Traumatology, University of Southern Denmark, Odense, Denmark
| |
Collapse
|
35
|
Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, Alegre-Sancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Marquez A, Martin J, Gómez-Reino JJ, Gonzalez A. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J 2015; 16:137-40. [PMID: 25896535 DOI: 10.1038/tpj.2015.29] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 02/16/2015] [Accepted: 03/02/2015] [Indexed: 01/21/2023]
Abstract
Genetic biomarkers could be useful for orienting treatment of patients with rheumatoid arthritis (RA), but none has been convincingly validated yet. Putative biomarkers include 14 single nucleotide polymorphisms that have shown association with response to TNF inhibitors (TNFi) in candidate gene studies and that we assayed here in 755 RA patients. Three of them, in the PTPRC, IL10 and CHUK genes, were significantly associated with response to TNFi. The most significant result was obtained with rs10919563 in PTPRC, which is a confirmed RA susceptibility locus. Its RA risk allele was associated with improved response (B=0.33, P=0.006). This is the second independent replication of this biomarker (P=9.08 × 10(-8) in the combined 3003 RA patients). In this way, PTPRC has become the most replicated genetic biomarker of response to TNFi. In addition, the positive but weaker replication of IL10 and CHUK should stimulate further validation studies.
Collapse
Affiliation(s)
- A Ferreiro-Iglesias
- Laboratorio de Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
| | - A Montes
- Laboratorio de Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
| | - E Perez-Pampin
- Laboratorio de Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
| | - J D Cañete
- Rheumatology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - E Raya
- Department of Rheumatology, Hospital Clínico San Cecilio, Granada, Spain
| | - C Magro-Checa
- Department of Rheumatology, Hospital Clínico San Cecilio, Granada, Spain
| | - Y Vasilopoulos
- Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece
| | - T Sarafidou
- Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece
| | - R Caliz
- Rheumatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - M A Ferrer
- Rheumatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - B Joven
- Reumatology Department, Hospital 12 de Octubre, Madrid, Spain
| | - P Carreira
- Reumatology Department, Hospital 12 de Octubre, Madrid, Spain
| | - A Balsa
- Department of Rheumatology and Institute for Health Research (IdiPAZ), University Hospital La Paz. Madrid, Spain
| | - D Pascual-Salcedo
- Immunology Unit, Instituto de Investigación Hospital Universitario La Paz, Hospital Universitario La Paz, Madrid, Spain
| | - F J Blanco
- Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain.,Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - M J Moreno-Ramos
- Department of Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain
| | - A Fernández-Nebro
- UGC de Reumatología, Instituto deInvestigación Biomédica de Málaga (IBIMA), HRU de Málaga, Universidad de Málaga, Málaga, Spain
| | - M C Ordóñez
- UGC de Reumatología, Instituto deInvestigación Biomédica de Málaga (IBIMA), HRU de Málaga, Universidad de Málaga, Málaga, Spain
| | | | - J Narváez
- Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
| | - F Navarro-Sarabia
- Rheumatology Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - V Moreira
- Rheumatology Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - L Valor
- Rheumatology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - R García-Portales
- Department of Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain
| | - A Marquez
- Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain
| | - J Martin
- Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain
| | - J J Gómez-Reino
- Laboratorio de Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain.,Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - A Gonzalez
- Laboratorio de Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
| |
Collapse
|
36
|
Burguera EF, Vela-Anero A, Magalhães J, Meijide-Faílde R, Blanco FJ. Effect of hydrogen sulfide sources on inflammation and catabolic markers on interleukin 1β-stimulated human articular chondrocytes. Osteoarthritis Cartilage 2014; 22:1026-35. [PMID: 24831018 DOI: 10.1016/j.joca.2014.04.031] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2013] [Revised: 04/13/2014] [Accepted: 04/30/2014] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Hydrogen sulfide (H2S), the third gasotransmitter together with NO and CO, is emerging as a regulator of inflammation. To test if it might offer therapeutic value in the treatment of osteoarthritis (OA) we evaluated the effects of two exogenous sources of H2S, NaSH and GYY4137, on inflammation and catabolic markers that characterize OA. METHOD Human chondrocytes (CHs) were isolated from OA tissue. Cells were stimulated with a pro-inflammatory cytokine (interleukin-1β, IL1β, 5 ng/ml) and the ability of the two H2S sources to ameliorate its effects on the cells was tested. Nitric oxide (NO) production was quantified through the Griess reaction. Protein levels of inducible NO synthase (NOS2) and matrix metalloproteinase 13 (MMP13) were visualized through immunocytochemistry (ICC). Relative mRNA expression was quantified with qRT-PCR. Prostaglandin-2 (PGE-2), interleukin 6 (IL6) and MMP13 levels were measured with specific EIAs. NFκB nuclear translocation was visualized with immunofluorescence. RESULTS Both H2S sources led to significant reductions in NO, PGE-2, IL6 and MMP13 released by the cells and at the protein level. This was achieved by downregulation of relevant genes involved in the synthesis routes of these molecules, namely NOS2, cyclooxigenase-2 (COX2), prostaglandin E synthase (PTGES), IL6 and MMP13. NFκB nuclear translocation was also reduced. CONCLUSION NaSH and GYY4137 show anti-inflammatory and anti-catabolic properties when added to IL1β activated osteoarthritic CHs. Supplementation with exogenous H2S sources can regulate the expression of relevant genes in OA pathogenesis and progression, counteracting IL1β pro-inflammatory signals that lead to cartilage destruction in part by reducing NFκB activation.
Collapse
Affiliation(s)
- E F Burguera
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain; Grupo de Bioingieneria Tisular y Terapia Celular (CBTTC), Servicio de Reumatología, Instituto de, Investigacion Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruna (CHUAC), A Coruña, Spain.
| | - A Vela-Anero
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain; Departmento de Medicina, INIBIC-Universidad de A Coruña, A Coruña, Spain.
| | - J Magalhães
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain; Grupo de Bioingieneria Tisular y Terapia Celular (CBTTC), Servicio de Reumatología, Instituto de, Investigacion Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruna (CHUAC), A Coruña, Spain.
| | - R Meijide-Faílde
- Departmento de Medicina, INIBIC-Universidad de A Coruña, A Coruña, Spain.
| | - F J Blanco
- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain; Grupo de Bioingieneria Tisular y Terapia Celular (CBTTC), Servicio de Reumatología, Instituto de, Investigacion Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruna (CHUAC), A Coruña, Spain.
| |
Collapse
|
37
|
Gago-Fuentes R, Carpintero-Fernandez P, Goldring MB, Brink PR, Mayan MD, Blanco FJ. Biochemical evidence for gap junctions and Cx43 expression in immortalized human chondrocyte cell line: a potential model in the study of cell communication in human chondrocytes. Osteoarthritis Cartilage 2014; 22:586-90. [PMID: 24530659 DOI: 10.1016/j.joca.2014.02.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Revised: 02/01/2014] [Accepted: 02/06/2014] [Indexed: 02/02/2023]
Abstract
OBJECTIVE The development of chondrocytic cell lines has enabled the investigation of the role of cellular phenotype and mechanisms in articular cartilage biology and physiopathology of several rheumatic diseases. Among them, the T/C-28a2 cell line has become a common tool in cartilage research. Recent results from our group have revealed that primary human chondrocytes in tissue and in monolayer culture contain high levels of connexin 43 (Cx43) and are able to directly communicate through gap junction (GJ) channels. These results challenge the existing thesis of cartilage physiology, that chondrocytes do not have the capacity to physically communicate with each other. Established cell lines offer the advantage of convenience and uniformity; however, the establishment process may cause a disruption of GJ. This study was performed to investigate if T/C-28a2 cells contain Cx43 protein and form functional channels. METHODS Cx43 was characterized by RT-qPCR, Western blotting, and immunohistochemistry (IHC). Electrophysiology experiments, Lucifer Yellow (LY) uptake, electroporation in situ and scrape loading assay were performed to test the functionality of GJs. RESULTS T/C-28a2 cells express Cx43. Electrophysiology experiments and LY uptake confirmed the capacity of these cells to communicate through GJ channels, although these cells contain significant levels of active c-Src kinase, presumably due to their immortalization with the Simian Virus 40 large T antigen. The results were validated using primary chondrocytes (PC). CONCLUSIONS These results reveal that the T/C-28a2 line may provide a useful in vitro model for the study of Cx43 function and cell communication to understand the physiology of chondrocytes and cartilage.
Collapse
Affiliation(s)
- R Gago-Fuentes
- Cartilage Biology Research Group, Rheumatology Division, INIBIC-Hospital Universitario A Coruña, Xubias de Arriba 84, 15006 A Coruña, Spain
| | - P Carpintero-Fernandez
- Cartilage Biology Research Group, Rheumatology Division, INIBIC-Hospital Universitario A Coruña, Xubias de Arriba 84, 15006 A Coruña, Spain
| | - M B Goldring
- Tissue Engineering Repair and Regeneration Program, The Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA
| | - P R Brink
- Department of Physiology and Biophysics, State University of New York, Stony Brook, NY, USA
| | - M D Mayan
- Cartilage Biology Research Group, Rheumatology Division, INIBIC-Hospital Universitario A Coruña, Xubias de Arriba 84, 15006 A Coruña, Spain.
| | - F J Blanco
- Cartilage Biology Research Group, Rheumatology Division, INIBIC-Hospital Universitario A Coruña, Xubias de Arriba 84, 15006 A Coruña, Spain; Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, Xubias de Arriba 84, 15006 A Coruña, Spain; Rheumatology Division, CIBER-BBN/ISCIII, INIBIC-Hospital Universitario A Coruña, Xubias de Arriba 84, 15006 A Coruña, Spain.
| |
Collapse
|
38
|
Birbara C, Blanco FJ, Crowley JJ, Hu C, Stevens R, Edwards CJ. OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.309] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Birbara C, Blanco FJ, Crowley JJ, Hu C, Stevens R, Edwards CJ. SAT0280 Efficacy of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis, Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.2005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Bejerano C, Blanco EA, Pinto-Tasende J, Pértega S, Rego I, Oreiro N, Lois A, De Toro J, Blanco FJ, Fernández-Sueiro JL. AB0574 Prevalence of hla-drb1 in psoriatic arthritis, psoriasis and rheumatoid arthritis: comparison with healthy controls. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Blanco EA, Bejerano C, Pinto-Tasende J, Pértega S, Rego I, Fernandez C, Freire M, De Toro J, Blanco FJ, Fernández-Sueiro JL. AB0575 Prevalence of hla-cw * 06 and * 07 and its relationship with psoriatic arthritis in northwestern spain. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2897] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
42
|
Calamia V, Lourido L, Mateos J, Fernandez-Puente P, Rocha B, Fernandez-Costa C, Montell E, Vergés J, Ruiz-Romero C, Blanco FJ. AB0074 Thrombospondin-1: a novel chondroitin sulfate target for osteoarthritis treatment. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Ferreiro-Iglesias A, Calaza M, Perez-Pampin E, Lopez-Longo FJ, Marenco JL, Blanco FJ, Narvaez J, Navarro F, Cañete JD, Rodriguez-de-la-Serna A, Gonzalez-Alvaro I, Herrero-Beaumont G, Pablos JL, Balsa A, Fernandez-Gutierrez B, Caliz R, Gomez-Reino JJ, Gonzalez A. THU0001 Replication of Interactions Between Polymorphisms in Rheumatoid Arthritis Susceptibility. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Panoutsopoulou K, Southam L, Elliott KS, Wrayner N, Zhai G, Beazley C, Thorleifsson G, Arden NK, Carr A, Chapman K, Deloukas P, Doherty M, McCaskie A, Ollier WER, Ralston SH, Spector TD, Valdes AM, Wallis GA, Wilkinson JM, Arden E, Battley K, Blackburn H, Blanco FJ, Bumpstead S, Cupples LA, Day-Williams AG, Dixon K, Doherty SA, Esko T, Evangelou E, Felson D, Gomez-Reino JJ, Gonzalez A, Gordon A, Gwilliam R, Halldorsson BV, Hauksson VB, Hofman A, Hunt SE, Ioannidis JPA, Ingvarsson T, Jonsdottir I, Jonsson H, Keen R, Kerkhof HJM, Kloppenburg MG, Koller N, Lakenberg N, Lane NE, Lee AT, Metspalu A, Meulenbelt I, Nevitt MC, O'Neill F, Parimi N, Potter SC, Rego-Perez I, Riancho JA, Sherburn K, Slagboom PE, Stefansson K, Styrkarsdottir U, Sumillera M, Swift D, Thorsteinsdottir U, Tsezou A, Uitterlinden AG, van Meurs JBJ, Watkins B, Wheeler M, Mitchell S, Zhu Y, Zmuda JM, Zeggini E, Loughlin J. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Ann Rheum Dis 2010; 70:864-7. [PMID: 21177295 PMCID: PMC3070286 DOI: 10.1136/ard.2010.141473] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Objectives The genetic aetiology of osteoarthritis has not yet been elucidated. To enable a well-powered genome-wide association study (GWAS) for osteoarthritis, the authors have formed the arcOGEN Consortium, a UK-wide collaborative effort aiming to scan genome-wide over 7500 osteoarthritis cases in a two-stage genome-wide association scan. Here the authors report the findings of the stage 1 interim analysis. Methods The authors have performed a genome-wide association scan for knee and hip osteoarthritis in 3177 cases and 4894 population-based controls from the UK. Replication of promising signals was carried out in silico in five further scans (44 449 individuals), and de novo in 14 534 independent samples, all of European descent. Results None of the association signals the authors identified reach genome-wide levels of statistical significance, therefore stressing the need for corroboration in sample sets of a larger size. Application of analytical approaches to examine the allelic architecture of disease to the stage 1 genome-wide association scan data suggests that osteoarthritis is a highly polygenic disease with multiple risk variants conferring small effects. Conclusions Identifying loci conferring susceptibility to osteoarthritis will require large-scale sample sizes and well-defined phenotypes to minimise heterogeneity.
Collapse
|
45
|
Rego-Pérez I, Fernández-Moreno M, Deberg M, Pértega S, Fernández-López C, Oreiro N, Henrotin Y, Blanco FJ. Mitochondrial DNA haplogroups and serum levels of proteolytic enzymes in patients with osteoarthritis. Ann Rheum Dis 2010; 70:646-52. [PMID: 21177294 DOI: 10.1136/ard.2010.133637] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To analyse the influence of mitochondrial DNA haplogroups, as well as the radiographic grade, on serum levels of proteolytic enzymes in patients with osteoarthritis (OA). METHODS Serum levels of metalloproteinase-1 (MMP-1), MMP-3, MMP-13, myeloperoxidase and cathepsin K were analysed in 73 patients with OA and 77 healthy controls carrying the haplogroups J, U and H, by ELISA. Knee and hip radiographs were classified according to Kellgren and Lawrence (K/L) scoring from grade 0 to grade IV. Non-parametric and multiple regression analyses were performed to test the effects of clinical variables, including gender, age, smoking status, diagnosis, haplogroups and radiological K/L grade on serum levels of these enzymes. RESULTS A significant influence of the haplogroups on the serum levels of MMP-3 and MMP-13 was detected (p=0.027 and p=0.035, respectively). Patients with OA with haplogroup H showed higher serum levels of MMP-3 than healthy controls. Serum levels of MMP-13 were significantly higher in patients with OA (p<0.001), and carriers of the haplogroup J showed lower levels than H carriers. Besides, levels of MMP-13 were proportionally higher in radiological groups B (K/L grade II and III) and C (K/L grade IV) than in group A (K/L grade 0 and I) (p=0.005). CONCLUSIONS This study shows that haplogroups have a significant influence on serum levels of MMP-3 and MMP-13. The influence of the haplogroups on serum levels of MMP-3 is clearly dependent on the diagnosis, whereas the influence of the haplogroups on serum levels of MMP-13 is independent of diagnosis.
Collapse
Affiliation(s)
- I Rego-Pérez
- Osteoarticular and Aging Research Laboratory, Biomedical Research Center, Complejo Hospitalario Universitario A Coruña, 15006-A Coruña, Spain
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Canete JD, Albaladejo C, Hernandez MV, Lainez B, Pinto JA, Ramirez J, Lopez-Armada MJ, Rodriguez-Cros JR, Engel P, Blanco FJ, Sanmarti R. Clinical significance of high levels of soluble tumour necrosis factor- receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study. Rheumatology (Oxford) 2010; 50:721-8. [DOI: 10.1093/rheumatology/keq381] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
47
|
Del Rey MJ, Izquierdo E, Usategui A, Gonzalo E, Blanco FJ, Acquadro F, Pablos JL. Transcriptional response to hypoxia of normal and rheumatoid arthritis synovial fibroblasts. Lab Invest 2010. [PMCID: PMC3007775 DOI: 10.1186/1479-5876-8-s1-p31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
48
|
Arufe MC, De la Fuente A, Fuentes I, de Toro FJ, Blanco FJ. Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes. J Cell Biochem 2010; 111:834-45. [PMID: 20665538 DOI: 10.1002/jcb.22768] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In this study we analyzed the chondrogenic potential of subpopulations of mesenchymal stem cells (MSCs) derived from human synovial membranes enriched for CD73, CD106, and CD271 markers. Subpopulations of human synovial membrane MSCs enriched for CD73, CD106, and CD271 markers were isolated using a cytometry sorter and characterized by flow cytometry for MSC markers. The expression of Sox9, Nanog, and Runx2 genes by these cells was measured by reverse transcriptase-polymerase chain reaction. The chondrogenesis of each subpopulation was assessed by culturing the cells in a defined medium to produce spontaneous spheroid formation and differentiation towards chondrocyte-like cells. The examination of the spheroids by histological and immunohistochemical analyses for collagen type II (COL2), aggrecan, collagen type I (COL1), metalloprotease 13 (MMP13), and collagen type X (COLX) levels were performed to assess their chondrogenesis capacity. The adipogenesis and osteogenesis potential of each subpopulation was determined using commercial media; the resulting cells were stained with oil red O or red alizarin to test the degree of differentiation. The subpopulations had different profiles of cells positive for the MSC markers CD44, CD69, CD73, CD90, and CD105 and showed different expression levels of the genes Sox9, Nanog, and Runx2 involved in chondrogenesis, undifferentiation, and osteoblastogenesis, respectively. Immunohistochemical analysis demonstrated that COL1, COL2, COLX, MMP13, and aggrecan were expressed in the spheroids as soon as 14 days of culture. The CD271(+) subpopulation expressed the highest levels of COL2 staining compared to the other subpopulations. CD105 and Runx2 were shown by immunohistochemistry and genetic analysis to have significantly higher expression CD271(+) subpopulation than the other subpopulations. Spheroids formed from CD271-enriched and CD73-enriched MSCs from normal human synovial membranes mimic the native cartilage extracellular matrix more closely than CD106(+) MSCs and are possible candidates for use in cartilage tissue engineering. Both cell types have potential for promoting the differentiation of MSCs into chondrocytes, presenting new possibilities for achieving intrinsic cartilage repair.
Collapse
Affiliation(s)
- M C Arufe
- Osteoarticular and Aging Research Lab, Cellular Therapy Unit, INIBIC-CH Universitario Juan Canalejo, 15006 A Coruña, Spain
| | | | | | | | | |
Collapse
|
49
|
Ruiz-Romero C, Blanco FJ. Proteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis. Osteoarthritis Cartilage 2010; 18:500-9. [PMID: 20060947 DOI: 10.1016/j.joca.2009.11.012] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2009] [Revised: 10/21/2009] [Accepted: 11/23/2009] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Osteoarthritis (OA) is the most common rheumatic pathology. It is related to aging and is characterized primarily by cartilage degradation. Despite its high prevalence, the diagnostic methods currently available are limited and lack sensitivity. The focus of this review is the application of proteomic technologies in the search of new biomarkers for improved diagnosis, prognosis and treatment of OA. METHODS This review focuses on the utilization of proteomics in OA biomarker research to enable early diagnosis, improved prognosis and the application of tailored treatments. RESULTS New diagnostic tests for OA are urgently needed and would also promote the development of alternative therapeutic strategies. Considering that OA involves different tissues and complex biological processes, the most promising diagnostic approach would be the study of combinations of biomarkers. New experimental approaches for the identification and validation of OA biomarkers have recently emerged and include proteomic technologies. These techniques allow the simultaneous analysis of multiple markers and become a very powerful tool for both biomarker discovery and validation. CONCLUSIONS Improvements in proteomics technology will undoubtedly lead to advances in characterizing new OA biomarkers and developing alternative therapies. Even so, further work is required to enhance the performance and reproducibility of proteomics tools before they can be routinely used in clinical trials and practice.
Collapse
Affiliation(s)
- C Ruiz-Romero
- Laboratorio de Investigación Osteoarticular y del Envejecimiento, Unidad de Proteómica-Nodo Asociado a ProteoRed-(Genoma España), Centro de Investigación Biomédica, Servicio de Reumatología, Complejo Hospitalario Universitario de A Coruña, 15006-A Coruña, Spain
| | | |
Collapse
|
50
|
Valcarcel-Ares MN, Vaamonde-Garcia C, Riveiro-Naveira RR, Lema B, Blanco FJ, Lopez-Armada MJ. A novel role for mitochondrial dysfunction in the inflammatory response of rheumatoid arthritis. Ann Rheum Dis 2010. [DOI: 10.1136/ard.2010.129643t] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|